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CHAPTER 1: GENERAL INTRODUCTION 
 
Statement of the problem 
Respiratory syncytial virus (RSV) is the most frequent cause of bronchiolitis in infants and children 
worldwide (1).  RSV was first discovered in 1955 in chimpanzees and two years later was isolated 
from an outbreak of respiratory disease in infants (2, 3).  In the 55 years since then, only one specific 
preventative measure, the humanized monoclonal antibody Palivizumab, and one therapy, the 
antiviral ribavirin, have been successfully developed for use in a clinical setting.  Early in vaccine 
trials of the 1960s, enhanced disease was induced in infants, resulting in severe disease, with 
hospitalization of 80% of vaccines versus <5% of controls and two mortalities (4).  While 
epidemiologic risk factors of severe disease are known, the underlying mechanisms of severe disease 
remain unknown. 
Many animal models including rodents and several other species have been utilized to study RSV, but 
most studies investigate disease in adult animals and fail to address the unique physiology and 
immunology that makes infants more susceptible to severe disease.  Our group and others have used 
the perinatal lamb to model infant RSV disease (5-9) as lambs have a similar pulmonary development 
and are susceptible to RSV.  Lambs develop mild clinical symptoms including fever, tachypnea, and 
malaise as well as mild to moderate gross and histologic lesions when experimentally infected with 
bovine or human RSV; preterm lambs develop more severe disease with bRSV (8, 10).  The lamb 
model has a strong foundation and forms a valid model for moderate disease as evidenced by clinical 
alteration of respiration as well as gross and histologic lesions, but there is need for a model of more 
severe disease. 
There are two primary strains of RSV, A and B, with many genetically divergent substrains of each.  
Memphis 37 is an RSV-A strain isolated from a pediatric case and used in studies in human adult 
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subjects (11).  Human RSV A2 strain replicates in lambs and causes disease (10) but other strains 
may have enhanced virulence.  Additionally, while bronchoscopic inoculation works well and has the 
benefit of very precise delivery with a fluid volume of virus into the bronchi, it may be beneficial to 
more closely mimic natural disease by administration of virus in the upper respiratory tract or in mists 
or aerosols.  This would allow a more natural deposition of viral particles as well as allow some of the 
upper airway defenses to be assessed. 
Specific Aims 
The overarching goal of the studies undertaken was to develop a model of enhanced RSV that could 
be utilized for investigating the pathogenesis of enhanced disease as well as therapeutic regimens.  
The central hypothesis for these studies was that Memphis 37 causes moderate to severe disease in 
neonatal lambs as measured by alterations in respiration as well as gross and histologic lesions.  This 
hypothesis was tested by 1) a pilot study using intranasally inoculated Memphis 37 at two different 
dosages in lambs (Chapter 2) 2) comparing disease in lambs with Memphis 37 virus grown in two 
different cell lines (Chapter 3) and 3) comparing Memphis 37 strain to A2 strain nebulized in lambs 
(Chapter 4).   
Dissertation organization 
This dissertation describes the characterization of Memphis 37 (M37) human respiratory syncytial 
virus (RSV) administered to neonatal lambs.  This dissertation is organized into five chapters.  The 
first chapter (Chapter 1) provides a general introduction and a literature review.  The three subsequent 
chapters (Chapter 2-4) are comprised of three individual manuscripts prepared for peer-reviewed 
journal submission.  The final chapter (Chapter 5) contains a general conclusion and directions of 
future research.  References appear at the end of each chapter.  The first manuscript will be submitted 
to American Journal of Respiratory Critical Care Medicine.  The second and third will target 
appropriate journals such as Respiratory Research, Veterinary Pathology, or other journals. 
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Literature Review 
Respiratory Syncytial Virus Morphology and Function 
Respiratory syncytial virus (RSV) is in the Paramyxoviridae family, subfamily Pneumovirinae.  The 
Pneumovirus genus includes human, bovine, ovine, and caprine respiratory syncytial viruses as well 
as murine pneumovirus (pneumonia virus of mice).  The four respiratory syncytial viruses are closely 
related while murine pneumovirus shares less homology.  As all viruses in order Mononegavirales, 
RSV is a single-stranded, negative sense RNA virus.  The virus codes for 11 proteins, including 3 that 
protrude from the viral envelope surface. 
The central nucleocapsid of viral particles is surrounded by a lipid envelope derived from host-cell 
membrane which is supported by a scaffolding of viral matrix protein (M).  The matrix not only 
provides structure for the envelope, but also has a role in virion assembly, interacting with the 
envelope proteins, and the nucleocapsid (12-14).  The nucleocapsid is formed by the negative-sense 
viral RNA that is closely associated and stabilized by a nucleocapsid protein (N) that also functions as 
a co-factor in transcription, small phosphoproteins (P), and the large polymerase that transcribes the 
nucleic acid (L).  A smaller 22 kDa protein (M2-1) is also present in the nucleocapsid.  M2-1 is bound 
to both P and viral RNA and forms part of the polymerase apparatus during transcription, acting as an 
elongation factor (15).  The remaining three proteins are all non-structural and produced in the 
infected cell, but not a component of viral particles.  The first two nonstructural proteins, 
nonstructural protein 1 (NS1) and nonstructural protein 2 (NS2), at the 3’ end of the genome are the 
first and most abundantly transcribed viral proteins upon viral entry into a host cell (16).  Both of 
these proteins act individually as homomers or as heteromers to antagonize and inhibit interferon 
production and action (17-19).  The final non-structural protein, M2-2, is not required for viral 
replication, but loss of this gene attenuates infectivity (20).   
The remaining three proteins are the surface proteins which are prime targets for disruption of viral 
entry.  The smallest of these is the small hydrophobic protein (SH), which is not necessary for viral 
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replication, cell entry, or syncytia formation although loss of this protein decreases viral replication in 
vitro and in vivo (21).  The SH protein may play a role in inhibiting cellular apoptosis, possibly 
through reduction of tumor necrosis factor alpha (TNFα) production (22).  Alternatively, it may act as 
a viroporin, altering host cell membrane permeability (23).   
The final two proteins are the attachment glycoprotein (G) and the fusion protein (F) (24, 25).  Of 
these two proteins only F is required for replication in vitro, but virus lacking the G protein is highly 
attenuated (21, 26).  Ultrastructural examinations have demonstrated that both proteins protrude from 
the viral envelope as spikes, exposing these two proteins to the host immune system prior to viral 
entry into host cells (27).  The poor adaptive immune response that occurs with natural infection 
targets antigens on these two proteins (28).  As its name implies, the G protein is heavily glycosylated 
which affects its antigenicity (29).  The G protein attaches to the host cell, primarily via 
glycosaminoglycans on the cell surface (25, 30).  More recently identified is a secreted form of the G 
protein which plays a role in immune evasion of the virus by acting as an antigen decoy (31).  Once 
attached, the F glycoprotein is activated and, similar to other paramyxoviruses, undergoes a 
conformational change that merges the viral envelope into the cell membrane (32).  The F protein also 
causes the cell to cell fusion to create the eponymous syncytia of RSV.  Given that F protein is 
necessary for infective virus (33, 34), is highly conserved (35, 36), and is present on the cell surface, 
it presents a highly attractive target for therapeutic immunogenicity.  Currently the only specific 
therapy for RSV is the humanized monoclonal antibody Palivizumab (Synagis®, MedImmune) which 
targets a highly conserved region of the F protein and prevents viral-cellular fusion (37).  
Unfortunately, cost-benefit analyses recommend administering Palivizumab only to high-risk infants 
(38) and compliance with administration guidelines can be poor (less than 30%) for a number of 
reasons (39, 40).  Thus, there remains a need to develop additional therapeutic options as well as 
continued research to better understand viral pathogenesis.  A new humanized monoclonal antibody, 
Motavizumab (Numax), intended to replace Synagis was developed by MedImmune/AstraZeneca; 
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however, it was rejected by the FDA due to concerns with skin reactions and a lack of superiority 
over Synagis.  Astrazenica discontinued the drug taking a $445 million loss in 2011(41). 
RSV Strain Differences 
 
The two main types of human RSV (hRSV) strains in circulation are subgroups A and B.  These 
differ mostly in the G protein, although significant differences occur in non-coding regulatory regions 
of the genome as well (35, 42, 43).  Both subgroups circulate in the general population, with 
predominance of one subgroup or the other in a given season and subgroup A is more commonly 
identified as the cause of disease (44-48).  The strains can co-circulate in an epidemic and there is 
significant genetic drift in both substrains, although the strains appear to have evolved separately (42, 
49).   
The Memphis 37 (M37) strain is a substrain of RSV A strain that was isolated from a pediatric case of 
bronchiolitis by Dr. John DeVincenzo (11) and has been maintained by Meridian Life Science in low 
passage.  This strain has been used in human subjects to cause upper respiratory disease in adults 
(11).  Other common human strains used in research include the Long strain, line 19 strain, and A2 
strain.  These are all subgroup A viruses.  A2 commonly occurs in natural disease outbreaks (48, 50) 
and was first isolated in 1961.   
The M37 strain has a truncated G protein when propagated in Vero cells.  The G protein is typically 
heavily glycosylated, primarily in the Golgi compartment, yielding an 84-92 kDa protein from the 
original 32kDa protein translated form viral mRNA.  Vero cells produce RSV expressing primarily a 
55-kDa G glycoprotein (51).  This parallels early studies in which RSV grown in HeLa cells differs 
from those grown in BSC-1 cells in which a large RSV glycoprotein (eventually named the G protein) 
was identified (25, 52, 53).  Both BSC-1 and Vero cells are derived from African green monkey 
kidney cells.   
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Disease Burden 
 
Human RSV is ubiquitous worldwide, causing a range of disease in infants to the elderly.  It is a 
major cause of acute low respiratory infection in infants and young children and the leading cause of 
infantile bronchiolitis worldwide (54).  In industrialized countries hRSV accounts for up to 70% of 
hospitalized bronchiolitis cases (55).  
Despite this massive disease burden, there is no vaccine, only Palivizumab for prevention, and a 
single antiviral therapy, Ribavirin.  Ribavirin is a synthetic nucleoside first tested on RSV in the early 
1980s after showing efficacy in plaque reduction and symptoms of influenza (56).   Early trials 
showed decreased viral shedding, higher oxygen saturation rates, lower illness scores, and faster 
improvement in lower respiratory-tract disease and no side effects (57, 58).  While Ribavirin has had 
few safety concerns over its nearly 30 years of use, repeated analyses fail to show significant 
difference in disease outcome with Ribavirin treatment (59-62).  This serious deficit in the therapeutic 
arsenal against RSV is not due to a lack of need, but rather caution after the 1960s clinical trial of a 
formalin-inactivated vaccine lead to enhanced disease, necessitating hospitalization of 80% of 
vaccine recipients including two fatalities (63).  Subsequent vaccine candidates have been not made it 
to clinical trials, yielded disappointing results in development of immunity, or remain in pre-clinical 
trials. 
Immunocompetent adults and children infected with RSV may experience a mild upper respiratory 
infection causing rhinorrhea (runny nose) whereas infants, young children, immunocompromised, and 
the aged more commonly develop upper and/or lower respiratory disease or, on occasion, otitis 
media.  For a small percentage of individuals RSV infection requires hospitalization. It is estimated 
that 3% of RSV cases in the United States and 10% of cases worldwide result in hospitalization, 
although the percentage of cases necessitating hospitalization varies widely by geographic region, 
year, and season (1, 55).  While this is only a small percentage of all cases, an estimate from a meta-
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analysis of the number of new cases of lower respiratory infection due to RSV in children under 5 in 
2005 was 33.8 million (64).  Other estimates of disease burden are as high as 64 million cases per 
year worldwide (54).  Additionally, while attack rates of severe RSV are higher in developing 
countries, hospitalization rates are lower.  As an example, in rural Kenya, the rate of severe lower 
respiratory tract infection was 4-5 times higher than the rate of hospitalization; by WHO guidelines 
all of these cases would be recommended for hospitalization (65).  While precise numbers are 
difficult to pinpoint and vary by study timing, region, and method of analysis, there is no doubt that 
RSV has a high morbidity rate, particularly among certain subsets of the population.  As one would 
expect, severe disease occurs more frequently in these subsets with higher overall morbidity.  Among 
infants, a number of risk factors of severe disease have been identified. 
Risk factors of severe disease in infants include premature birth, congenital heart defects, 
neuromuscular deficits, Down’s syndrome, immunodeficiency/compromise, and bronchopulmonary 
dysplasia (66-68).  Of these at- risk populations, the largest group is those born premature.  A recent 
United States survey reported premature birth rate at 12.3%, or approximately one half million (69).  
Worldwide, there are an estimated 13 million preterm  births (70).  While epidemiologic evidence can 
identify individuals at increased risk for RSV, the mechanisms of severe disease are poorly 
understood.  Although there are many animal models of RSV infection and numerous studies 
completed, the vast majority of these studies are performed in adult animals (or humans).  Lung 
structure, function, and immunological response of neonates and preterm infants differ significantly 
from that of adults (as discussed further below).  Thus, a neonatal model of RSV infection is needed 
to better understand disease mechanisms and immune responses and to assess vaccines and 
therapeutic regimens during infancy. 
Clinical Features of RSV Infection in Infants 
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While a small percentage of infants and young children infected with RSV are hospitalized, a larger 
number are seen as outpatient cases at pediatric units.  The clinical symptoms range from rhinorrhea 
to labored breathing and forced expiration that requires oxygen supplementation; however, infection 
rarely leads to death.  Bronchiolitis is the most common clinical diagnosis, although methods of 
arriving at this diagnosis vary (55).  Other diagnoses include upper respiratory tract infections, 
asthma, pneumonia, and otitis media (55, 71).  Of hospitalized patients, symptoms of lower 
respiratory infection include labored respirations (increased expiratory effort), wheezing, apnea, and 
hypoxemia (oxygen saturation below 90%, or 88% in infants <1 month of age) (1, 55).  Bronchiolitis 
can also be detected radiographically.  Among outpatients, symptoms of RSV can include rhinorrhea, 
cough, fever, labored respiration, hypoxemia, and wheeze (1, 55).  When comparing RSV-
bronchiolitis to nonRSV-bronchiolitis, RSV patients tend to have longer hospital stays, are more 
frequently admitted to the intensive care unit (ICU), and require supplemental oxygen for longer 
periods (71, 72).  The median hospital stay ranges from 3-9 days (71, 73, 74). 
After resolution of primary disease, up to 50% of RSV bronchiolitis patients develop a recurrent 
wheeze (75-77).  Whether there is a common predisposition to both more severe RSV disease and 
wheeze or if severe RSV predisposes to wheeze is still not known.  Some studies have shown a link 
between recurrent wheeze, atopy, and severe or early RSV disease (78-81).  While recurrent wheeze 
can persist for years, severe RSV early in life does not appear to be associated with wheeze in 
teenagers or adults (82).  Palivizumab treatment significantly reduced recurrent wheeze in infants 
with no family history of atopy or food-allergy, but did not significantly reduce incidence of recurrent 
wheeze in infants with such a history, giving weight to hypothesis that RSV does predispose to 
wheeze in non-atopic infants (83).   
The Innate Immune Response to RSV Lower Respiratory Infection in Infants 
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A discussion of pulmonary innate immune responses of infants must be prefaced by acknowledging 
the limitations in monitoring and measuring cytokine, chemokine, cellular, and humoral responses in 
infant lungs.  The methods used must generally be minimally invasive, which limits the amount and 
type of data that can be collected from local pulmonary response to RSV.  Additionally, variations in 
disease diagnosis as well as method of sample collection create difficulties in comparisons between 
studies.  However, given the available data pool, much has been discovered and described, if it is not 
always dogmatic.  More often than not, a peptide, protein, or cytokine is shown to be “significant”- 
that is, up- or down-regulated, but with difficult patterns of expression or variations in expression 
depending on age or sex.  
The initial disease caused by RSV infection has an acute onset and typically a fairly short duration, 
although there can be protracted or recurring symptoms after elimination of the virus (27).  There is a 
range of severity of disease, with some individuals at increased risk due to altered lung structure or 
function and potentially a reduced ability to develop an adaptive response compared to others that 
typically experience mild disease.  The physical innate barriers of mucous production, mucociliary 
elevator apparatus, submucosal gland secretions, and complex branching of the respiratory tree must 
initially be overcome by the virus to allow RSV to reach bronchiolar epithelium which is a key target 
cell for RSV infection and replication (84).  Bronchiolar epithelial cells have an active role in their 
own defense through the secretion of immunomodulatory compounds with innate anti-viral activity, 
as well as secretion of cytokines and chemokines upon infection to recruit immune cells to their 
defense.  
Submucosal glands are present in the nasal cavity, trachea, and bronchi of humans, cattle and sheep; 
however, rodents submucosal glands are limited to the upper airways (85).  Submucosal glands work 
in concert with respiratory epithelium to create an oxidative host defense system at the mucosal 
surface through production of lactoperoxidase (LPO) that works in concert with other enzymes and 
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molecules.  The adjacent epithelia transport thiocyanate (SCN-) to the epithelial surface and also 
produce hydrogen peroxide (H2O2) via intracellular dual oxidases (Duox) (86-88).  LPO secreted by 
the submucosal glands onto the air-surface liquid catalyzes the conversion of H2O2 and SCN- to 
oxythiocyanate (OSCN-).  The Duox/LPO system has microbicidal activity against multiple bacteria 
and viruses (87, 89).  In vitro assays that substitute I- for SCN- in the LPO/Duox system have shown 
killing of RSV on a level with bleach (90).  Submucosal glands also secrete lactoferrin and lysozyme, 
two important factors in innate immunity, especially in the air-surface liquid (ASL).  Lactoferrin is an 
antimicrobial glycoprotein that not only binds pathogens directly, but acts as an immunomodulatory 
protein and bridges the innate-adaptive immunity crossover (91-93).  Pneumocytes make minor 
contributions to the amount of lactoferrin and lysozyme present in ASL  (94).  Recognizing the role 
of submucosal glands in immunity is vital to understanding the shortcomings of rodent models of 
RSV disease, especially when studying RSV in infants where innate immunity contributes a greater 
proportion of the overall defenses as compared to adults.  As an alternative to vaccine development, 
which relies on adaptive responses, therapies modulating the innate response could be important in 
decreasing RSV severity in infants because the adaptive response is complicated, involving a variety 
of cell types ranging from conventional and plasmacytoid dendritic cells to cytotoxic T cells.  In 
contrast, innate immune responses require maturation and activity of a single cell type in some cases 
(e.g., surfactant protein A production by type II cells) or several cell types (epithelial and submucosal 
glands for Duox/LPO).      
As indicated, epithelial cells produce innate immune molecules with anti-RSV activity.  Surfactant 
proteins A and D (SP-A and SP-D, respectively) are collectins that bind pathogens with the globular 
head region (mannose-binding C-type lectin) and signal with the collagen-like tail.  Both SP-A and 
SP-D are produced and secreted into the airway by primarily type II epithelial cells with a lesser 
contribution by Clara cells.  SP-A and SP-D have been shown to be reduced in infants with RSV 
disease that require ventilator assistance (95).  In cultured cell studies, SP-A and SP-D mRNA 
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expression is increased by RSV infection, but protein expression is decreased, putatively through 
decreased translational efficiency (96).  SP-A binds to RSV F protein and increases viral clearance 
(97, 98). SP-D enhances phagocytosis and clearance of RSV in a mouse model (99).  Both SP-A and 
SP-D enhance RSV elimination (100).  Genetic polymorphisms in SP-A or SP-D are associated with 
altered severity of RSV infection (101-103).   SP-A and SP-D are produced by ovine lung epithelia 
(104). 
The human beta defensins (HBD) are antimicrobial cationic peptides also produced by respiratory 
epithelium, including pneumocytes and submucosal glands (105).  Human beta defensins 1-4 are 
produced in the respiratory tract; HBD-1 is constitutively expressed while HBD2-4 are inducible 
(106).  In vitro infection of lung epithelia induces HBD-2 production by TNF-α via a nuclear factor 
κβ (NF-κβ)-dependent mechanism.  Secreted HBD-2 then disrupts the viral envelope, interfering with 
viral entry into host cells (107).  Similar to the beta defensins, the human cathelicidin LL37 is a 
cationic antimicrobial peptide.  LL37 is stored in neutrophils and produced by other leukocytes as 
well as epithelium.  It can be up-regulated in disease and plays a role in direct microbial killing as 
well as in immunomodulation and apoptotic signaling (108-110).  Beta defensins (sheep beta 
defensin-1) is produced by ovine lung epithelia (111) 
Clara cells are non-ciliated bronchiolar epithelial cells with multiple roles in the airways.  Clara cells 
biometabolize xenobiotics (112),secrete immunomodulatory substances (113), and act as progenitor 
cells (114).  Just as type II pneumocytes serve as a proliferation pool to replace dead and damaged 
type I pneumocytes, Clara cells act as a progenitor for type II cells, forming a proliferation pool that 
is vulnerable to exhaustion, especially in neonates (115, 116), but also in chronic smokers (chronic 
toxin exposure) (117).  Further, damage to or dysfunction of Clara cells creates a proinflammatory 
environment due to the loss of their immunomodulatory secretions (118). In their immunomodulatory 
capacity, Clara cells secrete a unique protein: Clara cell secretory protein (CC10), also known as 
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CCSP, CC16, and uteroglobin.  CC10 is increased in BALF and serum during acute injury such as 
smoke inhalation or application of pneumotoxicants (naphthalene, 4-ipomeanol), but decreased in 
chronic or dysplastic airway dysfunction, such as asthma, chronic obstructive pulmonary disease 
(COPD), or bronchopulmonary dysplasia (BPD) (119).  Infants that developed bronchopulmonary 
dysplasia had lower levels of CC10 at birth than age-matched infants that did not develop BPD (120).  
Gene knockout studies performed in mice have shown increased inflammation and viral persistence in 
CC10-deficient mice when challenged with RSV; restoration of CC10 abrogated these effects (121). 
Amniotic levels of CC10 during midtrimester were significantly higher in women who had preterm 
premature rupture of membranes compared to women who did not, and this elevation of CC10 could 
be in response to a proinflammatory event (122). While CC10 is the most studied secretion of Clara 
cells, Clara cells also produce SP-A and SP-D (113, 123).   
If virus surpasses all of these aforementioned barriers, it primarily binds to epithelial cells of the 
lower airway (84).  As epithelial cells are compromised or lost due to viral infection, their own 
defenses are further lowered and dysregulated and the blood-gas exchange is compromised directly 
by cell loss as well as indirectly by the sloughed cells blocking small bronchioles.  Infected epithelial 
cells are not passively dependent upon rescue by leukocytes, but the epithelial cells themselves have 
an active role in modulating the immune response as well as the release of anti-RSV compounds such 
as SP-A and inflammatory mediators and interferons that prevent viral replication.  Epithelial cells are 
initially triggered by activation of pattern recognition receptors (PRRs), many of which are Toll-like 
receptors (TLRs).  These are highly conserved molecules that recognize pathogen-associated 
molecular patterns (PAMPs) common to many general groups of pathogens and classes of microbes.  
In RSV, PRRs include TLR-4 (124, 125), TLR-2 (126), TLR-6, TLR-3, and retinoic acid-inducible 
gene I-like receptor (RIG-I) (127).   
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TLR-4 is a cell-surface molecule associated with CD14 that recognizes LPS from Gram-negative 
bacteria and lipoteichoic acid from Gram-positive bacteria, and also the F protein of RSV (105, 124, 
125, 128).  Binding of the TLR-4/CD14 complex activates NF-κβ, eventually leading to secretion of 
IL-8, IL-10, IL-6, as well as increased expression of TLR-4 on epithelial cells (125, 128).  There is 
scientific dispute over the impact of two TLR-4 single nucleotide polymorphisms (SNPs).  Multiple 
studies found that a single SNP or a haplotype with two SNPs in the TLR-4 gene is associated with 
increased susceptibility to symptomatic RSV infection and premature birth (129, 130), while other 
studies had contrary findings (131-133).  Two dissenting articles examined a single SNP as opposed 
to the two-SNP haplotype.  The third looked at immune response to RSV in 7-9 year olds’ peripheral 
blood monocytes, as opposed to comparing epidemiologic RSV disease to the haplotype.   
TLR-2 and TLR-6 form a cell-surface heterodimer (105).  Binding of TLR-2 activates NF-κβ through 
a MyD88-dependent pathway, initiating production of interleukin 1-beta (IL-1β) (134).  Studies in 
knockout mice demonstrate TLR-2 and -6 signaling in leukocytes that stimulates an immune response 
to RSV (126). 
TLR-3 is an intracellular TLR, present on the endosomal surface and recognizing dsRNA (105).  RSV 
is a single stranded RNA virus, but in vitro studies have demonstrated that TLR-3 is activated during 
replication (pairing of template and daughter strands) and leads to increased CCL-5 (Regulated on 
Activation Normal T cells Expressed and Secreted (known as RANTES)) production (135).  
Downstream signaling typically leads to interferon alpha and beta (IFNα and IFNβ) transcription.   
RIG-I is an intracellular helicase that binds dsRNA and subsequently activates interferon regulatory 
factors 3 and 7 (IRF3 and IRF7) which are transcription factors for IFNα and IFNβ (105).  Unique to 
RSV infection, RIG-I in epithelial cells upregulates CCL-5 and interferon-inducible protein (IP10) in 
addition to its typical IFN-β upregulation (127). 
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Many of the PRRs described induce IFN upregulation.  IFN-α and IFN-β are Type I interferons.  
Type I interferons reduce viral replication in cells, typically through JAK-STAT pathways, as well as 
by upregulating MHC I, thereby indirectly promoting the killing of virus-infected cells (105); also by 
production of down-stream IFN products such as protein kinase R that disrupts viral translation (136), 
2’,5’-oligoadenylate synthetase 1 (OAS1) that activates an RNase L to cleave viral RNA (137), 
ISGylation that inhibits viral replication (138), and MxA protein that binds viral nuceleoprotein to 
prevent replication and transcription (139).  Unlike other myxoviruses, RSV is resistant to MxA 
protein, although there are increased levels of MxA in peripheral blood of RSV-infected children 
(140, 141).  RSV’s nonstructural proteins NS1 and NS2 work to disrupt interferons, with NS1 
disrupting IFN transcription and NS2 disrupting IFN signaling in the target cell (16).  A similar 
disruption of type I interferons by NS1 and NS2 working in concert at multiple points in the IFN 
pathway occurs in bovine RSV infection (17).  Since two of the 11 proteins of RSV aim to disable the 
interferon system, there may be therapeutic potential in counteracting the action of NS1 and NS2 to 
allow the immune system to better control RSV. 
Interferon gamma (IFN-γ) is considered a Th1 cytokine, produced by CD4 T cells to activate 
macrophages, but in early infection it is produced by natural killer (NK) cells, dendritic cells, and 
macrophages (105).  TGFβ and interleukin 10 (IL-10) inhibit IFN-γ (105).   IFN-γ inhibits viral 
replication and increases MHC I and MHC II cell surface expression as well as increasing 
transcription of MHC I-associated peptides involved in antigen processing.  Stimulation of 
macrophages by IFN-γ induces secretion of IL-1, IL-6, IL-8, and TNF-α (142).  IFN-γ has been 
associated with increased CC10 protein and there is evidence of its involvement in regulation at the 
transcriptional level (143).  Low IFN-γ in nasopharyngeal secretions has been associated with 
increased disease severity in RSV-infected infants (144).  This may indicate a skewing toward a Th2-
type response.   
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IL-1β, IL-6 and TNF-α are proinflammatory cytokines produced by macrophages and epithelial cells 
that act to increase acute phase protein production from the liver, recruit neutrophils, and activate 
complement (105).  A direct relationship has been demonstrated between IL-1β levels in pharyngeal 
secretions and severity of RSV disease (145).  Infection of healthy adults’ dendritic cells with RSV 
stimulates IL-1β production and secretion, as well as the proinflammatory cytokines TNF-α and IL-6 
(146).   
Interleukin 8, also known as CXCL-8 to reflect its protein structure, is a chemoattractant for 
neutrophils, basophils, and T cells that is secreted by monocytes, macrophages, fibroblasts, 
keratinocytes, and endothelial cells (105).  IL -8 is increased in nasal wash secretions of infants 1-6 
months old infected with RSV, and this increase is more pronounced in those with more severe 
disease (147).  In the same study IL-8 levels were correlated with an increased required duration of 
supplemental oxygen as well as a higher peak fractional inspired oxygen (147).  In a study comparing 
term to preterm infants that experienced RSV infection before six months of age a similar correlation 
between clinical severity score and IL-8 was found, but not in preterm infants (148).  This highlights 
the complexity of understanding how the immune response contributes to disease in infants.  As 
previously mentioned, signaling through TLR-4 via NF-κβ is one mechanism leading to increased IL-
8 (125).   
Interleukin 10 (IL-10) is primarily produced by leukocytes, particularly monocytes, and overall has a 
dampening effect on cellular recruitment through downregulation of class II MHC molecules and 
downregulation of Th1 cytokine production (105).  IL-10 is increased in nasal wash secretions of 
infants during RSV infection (149).  Intriguingly, elevated IL-10 during acute RSV infection is 
associated with post-bronchiolitis wheeze (150).  Heterozygosity of a SNP in the IL-10 gene was 
associated with a decreased incidence of severe RSV, but not associated with any difference in the 
incidence of post-bronchiolitis wheeze (150, 151).   
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TGF-β has a mixed effect on the immune response, activating neutrophils and typically inhibiting 
macrophage activation, although TGF-β does have the ability to activate or deactivate macrophages 
and monocytes depending on the rest of the cytokine milieu (105, 152).  TGF-β is produced by NK 
cells and macrophages in innate immunity as well as T and B cells as part of the adaptive immune 
response (153-155).  Proliferation and differentiation of CD4+ T cells is blocked by TGF-β, which 
may be associated with a general dysregulation of Th1/Th2 response in infants (156).  TGF-β also 
plays a role in immunoglobulin production and class switching (153). 
Macrophage inflammatory protein-1 (MIP) is a 4 member family of CC chemokines: MIP-1α 
(CCL3), MIP-1β (CCL4), MIP-1δ (CCL9/10), MIP-1γ (CCL15) (157).  MIPs are expressed by 
lymphocytes, monocytes or macrophages, and epithelial cells and are generally proinflammatory, 
recruiting macrophages (157).  MIP-1α and MIP-1β are the most thoroughly studied and well-
characterized of the MIPs.  Murine and in vitro studies show that MIP-1α expression is increased in 
RSV infection (158-161).  MIP1-α was increased in the nasopharyngeal secretions of infants with 
severe bronchiolitis (162). 
Monocyte chemotactic protein (MCP-1/CCL-2) is produced by epithelial cells and functions as a 
chemoattractant for monocytes, eosinophils, and T cells.  In vitro infection of human bronchiolar 
epithelial cells with RSV induces MCP-1 production (158, 163).  In adults with upper respiratory 
infection due to RSV MCP-1 is increased in nasal secretions during periods of viral shedding (164), 
although no publications have indicated a similar finding in infants. 
RANTES (CCL-5) is chemotactic for T cells, dendritic cells, eosinophils, NK cells, mast cells, and 
basophils.  Contrary to its name, it is not limited to production by T cells; production of RANTES has 
been reported in platelets, macrophages, eosinophils, fibroblasts, endothelial, epithelial, and 
endometrial cells (165).  Multiple studies on RSV severity and human polymorphisms in RANTES 
have yielded conflicting results (166-168), although an interaction or compound effect of 
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polymorphisms at multiple sites yielding specific haplotypes may explain those studies in which no 
significance was demonstrated (149, 169-172).  A higher ratio of IL-1 to RANTES in nasopharyngeal 
secretions of infants with RSV was associated with a more severe clinical score (173), and in another 
study there was an inverse relationship between level of RANTES in tracheal secretions and markers 
of clinical disease (174).  In vitro recombinant RANTES inhibited RSV infection of HEp-2 cells 
(175).  Low levels of RANTES in RSV infection could be due to a predisposed deficit or defect in 
RANTES production (as may be indicated by the haplotype studies), a direct blocking of RANTES 
by RSV, or indicate consumption during infection. 
The cytokines and chemokines reviewed here are not exhaustive, but emphasis has been placed on 
repeatable findings across multiple studies.  The following chemokines may be of future interest for 
evaluation of models of RSV disease, although current literature on their relationships to RSV is 
sparse.  Interleukin 17 (IL-17) stimulates neutrophil recruitment and stimulates fibroblasts and 
epithelial cells to secrete cytokines (105).  IL-17 was not detected among a population of healthy 
infants 1-6 months old while it was detected in 15% of RSV-infected infants in the same age range 
(147).  Interferon γ-inducible protein 10 (IP10/CXCL10) is considered a marker of Th1 response and 
is increased during RSV infection, although its receptor, CXCR3, is decreased when compared to 
control subjects (176).  Interleukins 19 and 20, which are related to IL-10 and induce TNF-α and IL-6 
(105), are related to a post-bronchiolitis wheeze similar to IL-10 (177). A polymorphism in 
interleukin 9 (IL-9) has an opposite effect in boys versus girls, associated with increased 
susceptibility in boys and protection in girls to severe RSV infection (178). 
The effector cells of innate immunity include vascular endothelium as well as leukocytes.  The 
vascular endothelium serves a pivotal role in the innate-adaptive immunity interface, responding to 
innate signals to recruit lymphocytes as well as altering the permeability of the vascular system to 
allow entry of serum.  Serum can dilute microbial agents and provide additional antimicrobial factors 
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such as complement, antibodies, and collectins.  The leukocytes of innate immunity include 
neutrophils, macrophages, dendritic cells, NK cells, eosinophils, and mast cells.  There is significant 
correlation between clinical severity score and total nasal wash leukocyte counts in term but not 
preterm infants (148).   
While some reference has been made to Th1 or Th2 cytokines, the primary focus of this review is on 
innate immunity since infants have a limited adaptive immune response.  However, there is 
considerable overlap during the transition from innate to adaptive immunity, as a number of the above 
innate factors are integral to priming and directing the adaptive response. Advances in innate 
immunity understanding will help put the adaptive response in context as well as create an overall 
picture of RSV disease and immunity.  From the above review, it is clear that the innate immune 
response is important in RSV infection, and a better understanding of it, as well as how to modulate 
it, could make a significant contribution to RSV therapy in infants.  
Differences Between Infant and Adult Lung 
 
The structural differences between infant and adult lung at the alveolar level include fewer as well as 
thicker-walled alveoli in the infant (179).  While the primary effect of this difference is on overall 
decreased efficiency of gas exchange, its implication in disease is more severe clinical symptoms with 
less inflammation.  Airway submucosal glands are present in the human trachea at 13 weeks’ 
gestation with rapid progressive appearance in the more distal areas; however, the gland is present but 
its structure is primitive, lacking the branching of more mature glands (180).  The number and type of 
Clara cells increase in the lung during fetal and perinatal development (181, 182).  As progenitor 
cells, Clara cells at different stages of maturity are identified by ultrastructural characteristics (183). 
While Clara cell secretory protein can be expressed as early as 10 weeks of gestation in humans 
(184), and almost certainly by 15 weeks gestation (181) the production of CCSP of Clara cells 
indicates a presence of cells but not necessarily maturity.  Bronchiolar epithelial cells in regions with 
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abundant Clara cells are infected by RSV (185) and immaturity of Clara cells may play a role in 
increased susceptibility of premature infants to RSV.  Additionally, CC10 levels vary throughout the 
course of RSV disease, indicating an interaction, direct or indirect, of the primary secretory product 
of Clara cells and the virus (121) 
Cells of the innate immune system are decreased in number and often operate with decreased 
efficiency.  Dendritic cells (DCs) in neonates are reduced and the ratio of myeloid to plasmacytoid 
DCs is inversed as compared to adults.  Neonatal DCs have a reduced ability to produce IFN and 
decreased ability to stimulate a Th1 response, although contrary to observations in mice this 
difference alone does not predispose infants to a Th2-skewed response (186).  Dendritic cells are 
important in the neonatal response to RSV infection, with increased numbers present in nasal washes 
of infants with severe RSV (156).  Neonates have a reduced proliferation pool as well as a reduced 
storage pool of neutrophils and those in circulation have an impaired response to chemotaxins and 
deficiencies at multiple stages of migration including rolling adhesion, transmigration, and 
lamellipodia formation.  Once at the site of infection, neutrophils of infants do not function at the 
same level as those of adults (187).  They have about half the amount of lactoferrin, a 30% reduction 
in bactericidial/permeability increasing protein (BPI), and impaired oxidase activity (188-190).  
Neutrophils are a key component in RSV pathology, with an influx into bronchioles and, to a lesser 
extent, alveoli (191).  Neutrophils undergoing NETosis (a form of neutrophil apoptotic-like death 
mediated by pathogens) can release neutrophilic extracellular traps (NETs) composed of DNA 
strands, histones, and antimicrobial peptides such as cathelicidins which can entrap bacteria and have 
antibacterial activity (192).  NETs have not been linked with RSV, but illustrate a mechanism of 
damage induced by neutrophils.  NETs have not been linked with RSV, but illustrate a mechanism of 
innate protection induced by neutrophils and may have a role against bacterial infections secondary to 
RSV.  Neutrophilic inflammation in any individual is always in a precarious balance between killing 
of pathogen and damage to native tissue.  Impaired recruitment and function may be in some degree 
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preventative of collateral damage to lung tissue, but it also decreases the efficiency of pathogen 
killing, while the presence of neutrophils in small airways contributes to the clinical symptoms of 
labored breathing (increased expiratory effort, abdominal breathing) and wheeze.   
Both the cytokines that are elicited upon RSV infection as well as the response to them can be 
different when comparing adults to neonates.  Co-cultures of RSV-infected DCs and T cells of either 
adults or umbilical cord blood elicited markedly different cytokine profiles with the primary 
differences attributed to differences in response to TGF-β (156).  The response to chemokines in 
neonates varies from adult response due to the altered number and function of leukocytes as well as 
altered receptor expression.  In vitro stimulation of neonatal monocytes and antigen presenting cells 
shows decreased expression of TNF-α, IFN-α, IFN-γ, IL-12, and IL-1β, but increased expression of 
IL-6, IL-8, and IL-10 (187).   
Lambs as a Model of hRSV 
 
As indicated, extreme caution is exercised in vaccine development due to the tragedy of the formalin-
inactivated RSV vaccines used in the 1960’s.  In addition to the early vaccine disaster, there is lack of 
a fully satisfactory model to study infant disease and immune responses to RSV infection.  As 
recently reviewed by Bem, Domachoswke, and Rosenberg, a number of animal models have been 
used to recapitulate aspects of the different manifestations of human RSV disease (193).  Given that 
infants have both the highest rates of morbidity and mortality, a specific model of neonatal disease 
will be required to address the unique aspects of RSV disease in this population.  While no animal 
model perfectly mimics all forms of human disease, the neonatal lamb lung bears a close resemblance 
in airway structure and development as well as submucosal gland and Clara cell distribution to 
humans that is not present in common rodent models (194-196).  Ovine respiratory epithelia of 
airways, distal bronchioles and alveoli are similar to those of human lung whereas mouse lung has a 
large (50%+) population of Clara cells in bronchiolar airway, compared to ~22% in terminal 
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bronchioles in humans (114).  The Clara cells of sheep have ultrastructural features more similar to 
human Clara cells than most other species (197). 
The cell type and distribution in sheep have a profound effect on the immune system, as ovine 
submucosal glands contribute to the LPO system (86) and Clara cells have an important role in 
airway immunomodulation and repair.  On a subgross level, sheep have an airway branching pattern 
that is more similar to humans than the branching pattern present in rodent lung (85).   
Lambs are naturally susceptible to RSV and can be experimentally infected with either bovine RSV 
(bRSV) or hRSV (6-8, 10).  Infection with bRSV in neonatal (1 week old) as well as older (6 month 
old) lambs will cause clinical disease exhibited as fever, listlessness, and tachypnea, as well as gross 
and histologic lesions, including gross consolidation in the lung with histologic epithelial necrosis and 
influx of neutrophils, macrophages, and fewer lymphocytes (6, 7).  bRSV primarily infected 
bronchiolar epithelium and type I pneumocytes, but also type II pneumocytes, macrophages, and rare 
intravascular monocytes (5).  Infection of neonatal lambs with another paramyxovirus, parainfluenza-
3 (PI-3), caused increased mRNA expression of sheep beta defensins-1 (SBD-1), SP-1, and SP-D that 
was associated with viral clearance; protein levels of SP-A did not change throughout the course of 
disease (198).  Infection of preterm lambs with bRSV resulted in enhanced disease and decreased 
viral clearance compared to term lambs (8).  bRSV positive cells selected from post-mortem lung 
tissue by laser capture microscopy (LCM) had higher SP-A and MCP-1 mRNA in term and preterm 
lambs and higher SP-D in infected preterm lambs (104). 
The Long strain of RSV-A and type B RSV will infect lambs and cause clinically detectable RSV 
disease (199).   Similar to bRSV, hRSV strain A2 infected neonatal lambs, causing fever and inducing 
pulmonary lesions similar to those observed with bRSV in lambs (10).  In these lambs at day 3 post-
inoculation (p.i.) there are increased mRNA levels of TNF-α and IL-10 as well as increased TNF-α 
protein in lung tissue.  At 6 days p.i. IFN-γ, IL-8, MCP-1, and MIP-1α mRNA levels are increased in 
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infected levels compared to controls while IFN-β, TNF-α, TGF-β, IL-10, and RANTES mRNA are all 
decreased by infection with RSV.  At 14 days p.i. the following mRNA levels are decreased in 
infected compared to control: IFN-β, IFN-γ, TNF-α, TGF-β, IL-10, IL-8, MCP-1, and RANTES 
(200). 
Using the bRSV lamb model, vascular endothelial growth factor (VEGF) administered before viral 
inoculation was shown to have a protective effect with decreased inflammation and viral replication 
(9).  A similar protective effect of VEGF was shown using hRSV A2 (201).  VEGF induces TLR-4 
gene expression and delays anti-inflammatory mediators TGF-β and IL-10, decreasing their 
expression at 16 and 24 hours then increasing expression at 32 hours as compared to control lambs 
(202). 
Ontogeny studies of ovine lung tissue in some studies showed reduced mRNA of SP-A, SP-D, and 
SBD-1 in preterm tissues (104, 203), while another study showed no significant difference in 
surfactant mRNA and very low levels of SBD-1 in prenatal and neonatal tissue versus significantly 
higher levels in adult sheep (204).  Messenger RNA expression of TLR- 4 and -8 in the lung increases 
throughout gestation but for a sharp drop in TLR-4 mRNA levels in newborn lambs (204).  
Pulmonary TLR-7 mRNA is also significantly lower in newborn lambs than in preterm or adult 
animals (204).  Newborn and adult lambs have similar levels of TLR-3 expression in lung, but 
preterm lambs have significantly higher levels (204).  IFN-γ, TNF-α, IL-6, IL-8, and MCP-1 
increased throughout prenatal development, peaking at birth and decreasing into adulthood (204).  
The ovine innate immune system overall is quite dynamic throughout ontogeny. 
Overall, lambs provide a unique model of neonatal RSV that will be useful in exploring disease 
mechanisms, such as causes of increased severity and persistent effects of RSV infection, and 
valuable for use in pre-clinical trials of vaccines or therapeutics.    
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Abstract 
Rationale: Respiratory syncytial virus (RSV) is the leading cause of hospitalization due to respiratory 
illness in infants and children of industrialized countries. Despite the ubiquity of this disease and its 
potential for severity, there is a decided lack of understanding severe disease mechanisms as well as 
few available treatment options, none of which are fully satisfactory.  This is due, at least in part, to 
lack of an animal model of perinatal RSV infection that mimics moderate to severe disease in infants.  
The Memphis 37 strain of human RSV has been used to produce mild to moderate upper respiratory 
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clinical disease in healthy adult volunteers.  Previously, we and others have shown mild to moderate 
disease as evidenced by post-mortem lesions in perinatal lambs with either a bovine or a human A2 
strain of RSV.   
 
Objective: We hypothesized that the Memphis 37 strain of RSV (M37) would infect perinatal lambs 
and produce clinical disease.   
Methods: To test this, 3-5 day old lambs (n = 7) were inoculated intranasally with 2 mL/nostril 1 x 
105 PFU/mL or 2.1 x 108 PFU/mL Memphis 37.  Clinical signs, gross and histological lesions, 
immune and inflammatory responses were assessed.  
Results: Memphis 37 caused moderate to severe gross and histologic lesions including bronchiolitis 
with syncytial cell formation in perinatal lambs along with increased mRNA expression of 
macrophage inflammatory protein.  Clinically, 4/5 of the infected lambs had a mild to severe increase 
in expiratory effort.  The lesions and immune responses parallel those observed in human infants 
infected with RSV and demonstrate an infection capacity similar to or greater than other RSV strains.   
Conclusion: Intranasally administered Memphis 37 strain RSV infects neonatal lambs with gross, 
histologic, and clinical responses similar to those in human infants and other RSV strains. 
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Introduction 
Respiratory syncytial virus (RSV) is an enveloped RNA virus in the Paramyxoviradae family that 
causes variable levels of disease severity in all age groups from infants to the aged.  Most commonly, 
RSV causes a mild upper or lower respiratory disease with cold-like symptoms but in a small 
percentage of patients, particularly the very young, severe disease can occur.  Nearly every child in 
the United States has been infected with RSV at least once by age two (1).  Because of its ubiquity, 
the low percentage of severe disease yields a significant number of hospital cases: 85,000-144,000 
infants with RSV infection are hospitalized annually in the United States alone (2).  This constitutes 
20-25% of the pneumonia cases and up to 70% of all bronchiolitis cases in the hospital (3, 4).   
Treatment currently is limited to supportive care and one of two FDA-approved treatments (5).  Two 
major stumbling blocks in development of preventative and treatment regimens have been the 
disastrous initial vaccine clinical trial (6) and the lack of an available, clinically relevant model of 
human disease.  Rodents, while a valuable tool in RSV research, undergo post-natal alveolar 
development as opposed prenatal alveologenesis that occurs in humans and sheep (7-9).  
Additionally,  sheep and humans share a number of upper and lower airway traits including: airway 
branching pattern, nasal lymphoid tissue distribution, alveolar size, submucosal gland type and 
distribution, cartilage distribution, sensory nerves, airway capillary physiology, mast cell distribution, 
mucus-secreting cells, number of Clara cells in bronchioles, histamine effects, and cough/wheeze 
response (10).  Natural RSV disease occurs in cattle and sheep with bovine respiratory virus (bRSV) 
and has a similar presentation: seasonal outbreaks of highly contagious, mild respiratory disease with 
infrequent severe disease that occurs in conjunction with other pathogens (11, 12).  A bovine model 
of RSV infection has been used by a number of groups and is useful in mimicking human disease, but 
limited by the cost of feed and housing and typical birth of a single offspring in cattle.  Additionally, 
there is current use of a number of efficacious vaccines in cattle, as opposed to the current situation in 
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humans (11). Sheep are a particularly attractive model because of their smaller size, reduced cost, and 
increased offspring/parity when compared to cattle, and more human-relevant pulmonary 
development and structure compared to rodents.  Also, newborn and preterm lambs have increased 
RSV disease severity compared to older lambs (13-15), and histopathology of RSV lesions in lambs 
(and cattle) is similar to that seen in human infants (13, 16).   
In this study perinatal lambs were inoculated with hRSV Memphis strain 37 (M37) intranasally using 
an atomizer.  This intranasal route was used to more closely mimic natural disease; a similar method 
has been used to cause upper airway disease in humans with the M37 strain (17).  Previously, our 
group has administered virus (bRSV or hRSV A2 strain) intratracheally or intrabronchially (15, 18, 
19).  It was our hypothesis that intranasal inoculation of M37 hRSV would produce clinical disease 
and pathology paralleling that in human neonates.  Our results demonstrate that M37 can cause 
consistent, moderate disease at 6 days post inoculation (p.i.).  Gross and microscopic lesions were 
similar to those reported in human infants as was a clinical expiratory effort that was seen in infected 
lambs. 
Materials and Methods 
Experimental Design 
Animal use and experimental procedures were approved by Iowa State University’s Animal Care and 
Use Committee.   
Pilot study.  A pilot study was completed in order to determine the potential susceptibility of young 
lambs to Memphis 37 RSV strain.  The pilot study included four lambs (2-5 days of age). One lamb 
was inoculated intranasally (2 mL/nostril, 1 x 106 PFU).  Three were inoculated with a fiberoptic 
bronchoscope.  In two of these, the bronchoscope was inserted to the level of the mainstem bronchus 
just distal to the tracheal bifurcation and lambs received 8 or 17 mL; the final lamb received 10 mL in 
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the deep airway of the right cranial lobe.  Clinical features were recorded daily and lung tissues were 
collected six days post-inoculation.  
Intranasal study.  Neonatal lambs (2-3 days of age) were randomly assigned to three groups, a control 
group (n = 2), a low-dose RSV inoculated group (n = 2), and a high-dose RSV inoculated group (n = 
3).  Each lamb received 2 mL/nostril of inoculum administered via a syringe attached to a mucosal 
atomization device (MAD) (Wolfe Tory Medical, Inc., Salt Lake City, UT, USA).  Control lambs 
were inoculated with cell growth media; low-dose lambs were inoculated with the Memphis 37 strain 
of human respiratory syncytial virus grown in HEp-2 cells at 1 x 105 PFU/mL; high-dose lambs were 
inoculated with the same virus (M37 hRSV in HEp-2 cells) at 2.1 x 108 PFU/mL.  Four lambs 
received the high dose inoculum, but one lamb appeared to expel this shortly after inoculation and 
was excluded from the study.  Viral inocula were provided by Meridian LifeScience (Memphis, TN, 
USA).  Lambs were given daily antibiotics ((Ceftiofur, Pfizer, New York, NY) 1-2 mg/kg, 
intramuscular) to prevent secondary bacterial infection.  Lambs were monitored daily for clinical 
signs of respiratory disease and overall health.  Animals were euthanized by sodium pentobarbital 
(Beuthanasia, Schering Plough Animal Health, Union, NJ) overdose on day 6 p.i. 
Post-mortem 
After euthanasia the thorax was opened, lungs were removed, and gross lesions were scored (as 
described previously (19) and photographed ex vivo.  Tissue samples were collected from each lung 
lobe of all animals in the same manner. Briefly, multiple samples from each lobe were snap frozen in 
liquid nitrogen for RT-qpCR, two samples from each lobe were placed in tissue cassettes and put in 
10% neutral-buffered formalin for histological and immunohistochemical analysis.   
Fluorogenic one-step real-time quantitative PCR (RT-qPCR) 
Whole vials of right and left cranial, right and left middle, and accessory lobes were homogenized in 
TRIzol (Invitrogen, Carlsbad, CA, USA), then pooled for each animal to create a composite slurry.  
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RNA isolation continued per manufacturer’s instructions (Invitrogen), followed by DNase treatment 
(Ambion, TURBO DNase, Austin, TX, USA), then diluted 1:10 with a combination of RNaseOUT 
(Invitrogen) and nuclease-free water (Invitrogen).  Spectrophotometry (NanoDrop, Thermo Scientific, 
Waltham, MA, USA) was used to assess each sample for purity and quantity.  Fluorogenic one-step 
RT-qPCR was carried out using One-Step Fast qRT-PCR Kit master mix (Quanta, BioScience, 
Gaithersburg, MD, USA) in a GeneAmp 5700 Sequence Detection System (Applied Biosystems, 
Carlsbad, CA, USA) employing PREXCEL-Q for all set up calculations (20).  The following targets 
were assessed: M37 RSV (M37), Clara cell secretory protein (CC10), surfactant protein A (SP-A), 
interleukin 8 (IL-8), interleukin 10 (IL-10), macrophage inflammatory protein (MIP-1α), monocyte 
chemotactic protein (MCP1α), tumor necrosis factor alpha (TNF-α), interferon beta (IFN-β), 
interferon gamma (IFN-γ), and regulated on activation normal T-cell expressed and secreted 
(RANTES).  Primer and probe sequences (Table 1) have been previously used in our lab with the 
exception of the M37 forward primer.  All sequences were generated using ABI Primer Express 2.0 
software.  All samples were diluted to achieve a final RT-qPCR concentration of 0.7844 ng/µL.  Each 
sample was assessed in duplicate and each target gene amplification Cq converted to a relative 
quantity (rQ) based on the standard curve and using the following equation: rQ
 
= 10((Cq-b)/m), where Cq 
is the target quantification cycle, and b and m are the y-intercept and slope, respectively, from the 
Stock I standard curve for each target (20).   
Gross Lesion Evaluation and Scoring 
After removal, percentage parenchymal involvement was estimated for each lung lobe.  Percentages 
were converted to a scale using the following formula: 0% = 0, 1-9% = 1, 10-39% = 2, 40-69% = 3, 
70-100% = 4.  Group averages were calculated for the gross lesion score. 
Histologic Evaluation and Scoring 
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A histologic score was given by determining percent consolidation followed by conversion to a 
consolidation scale used by our laboratory previously (19): 0% consolidation = 0, 1-9% consolidation 
= 1, 10-39% consolidation = 2, 40-69% consolidation = 3, 70-100% consolidation = 4.  Group 
averages were calculated for the alveolar consolidation score. 
Immunohistochemistry 
Immunohistochemistry for RSV antigen was performed on paraffin-embedded tissue as described 
previously (21), with the following variations: instead of  Pronease E antigen retrieval, heated buffer 
antigen retrieval was performed in TE, pH 9.0 with microwave heating just to boiling followed by 30 
minutes in a pre-warmed steamer and cooling for 5 minutes on ice.  Primary polyclonal goat anti-
RSV antibody (BioDesign/Meridian, San Ramon, CA, USA) was applied for 2 hours at room 
temperature (~20°C) at a concentration of 1:300 instead of 1:50 as previously described.  Color was 
developed using Nova Red (Vector, Burlingame, CA, USA), counterstaining with Harris’ 
hematoxylin, after which slides were dehydrated and cover-slipped.  Slides were then scored by the 
following method: each slide containing two pieces of lung tissue had twenty 10X fields assessed for 
antigen staining.  Immunopositive cells were counted, then converted to a score where 0 = 0, 1-10 = 
1, 11-39 = 2, 40-99 =3, ≥ 100 = 4.  The number of fields per slide with antigen staining was also 
recorded.  Composite numbers for both number of fields with antigen staining and score were 
assessed. 
Virus Isolation 
Composite slurries of right and left cranial, right and left middle, and right and left caudal lobes were 
homogenized in phosphate buffered saline.  The composite homogenate was centrifuged (13,000 rpm, 
5 minutes at room temperature) and the supernatant was filtered across a 0.45µm membrane in a 
SpinX column (Corning, Costar, USA).  This filtrate was diluted 1:2 with DMEM plus 10% fetal 
bovine serum and used for plaque assay and immunofluorescence (IF).  For the plaque assay 500µL 
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of each filtered lung homogenate was diluted 2, 20, and 200-fold in duplicate. Plaques were counted 
after 5 days.  For immunofluorescence verification 500µL of lung homogenate was diluted 2-fold on 
a well of a 6-well plate with coverslip and stained by immunofluorescence with anti-hRSV Fusion 
protein monoclonal antibody (Meridian).  
Statistical Analysis 
All analyses were performed using GraphPad Prism 5.  All post-mortem data was assessed with one-
way ANOVA followed by Tukey’s post-test.  All clinical data was assessed with two-way ANOVA 
and cumulative weight change was additionally assessed with one-way ANOVA followed by Tukey’s 
post-test.  
Results 
Pilot study.  At day 6 p.i., 4/4 lambs had gross and microscopic lung pathology (epithelial 
degeneration and syncytia; neutrophils and debris in bronchioles/alveoli; lymphocytic infiltrates).  
Inoculation intranasally (2 mL/nostril) produced bilateral lung lesions.  Lambs inoculated directly into 
mainstem bronchus (8 or 17 mL) or into deep airway (10 mL) produced local lesions that were 
intense, occupying 60-90% of the lung lobe.  Daily body temperature was significantly higher (102.2 
vs. 103.6°F) at day four p.i. than day 0.  One lamb had mildly increased expiratory effort on days 4-6 
p.i.  Combined tissues from all lung areas (day 6 p.i.) had max 4.63 log PFU/gm by viral isolation in 
HEp-2 cells.  Histologic lesions were present in all infected lambs and were similar to those described 
previously for RSV in lambs (13, 15). Briefly, lambs had bronchiolitis with multifocal bronchiolar 
epithelial cell necrosis and mild to moderate hyperplasia of nearby epithelial cells; intraluminal 
infiltrates of neutrophils, the presence of occasional syncytial cells, and accumulation of cell debris 
within bronchioles; mild to moderate peribronchiolar infiltrates of lymphocytes and plasma cells in 
the adventitia; mild to moderate alveolar type II cell hyperplasia and minimal intraseptal infiltrates of 
lymphocytes. 
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Intranasal Study 
Clinical and post-mortem findings 
In the high-dose group 3/3 lambs had increased expiratory effort (i.e., forced expiration; abdominal 
breathing), first observed on day one in one lamb, and then noted in all three subjects by day four.  
Group score averages for the high-dose group were significantly higher than control (0) on days 5 and 
6 p.i. (Figure 1).  While there was no difference in weight gain on any given day, total weight gain in 
the high-dose group was significantly lower than either the control or low-dose group.  No significant 
difference in weight gain was noted between the control and low-dose groups (Figure 1).  There was 
no significant change in any other clinical parameter.  All 5 infected lambs had multifocally to locally 
extensively dark red, well-demarcated foci of pulmonary consolidation which varied in severity from 
moderate to severe (Figure 2).  These were slightly firm to rubbery on palpation.  The three high-
dose lambs had more extensive lesions than the two low-dose lambs on a basis of percentage tissue 
involvement.  Gross lesion scores (based on percentage of lung parenchyma involved) of the high-
dose group were significantly higher than either the control or low-dose group (Figure 2).   
Histopathology  
Infected lambs had multifocal to confluent foci of cellular infiltrate that filled bronchioles and alveoli 
and expanded the alveolar interstitium consistent with RSV infection reported previously in lambs 
(13, 19). This infiltrate was composed of lymphocytes, neutrophils, macrophages, and plasma cells.  
Bronchioles and alveoli contained moderate to abundant amounts of sloughed, degenerate epithelial 
cells and neutrophils.  Large epithelial syncytial cells were numerous within bronchioles.  Pulmonary 
epithelium lining affected alveoli an small bronchioles was thickened in areas by plump cuboidal 
cells with oval, vesiculate nuclei (type II pneumocyte hyperplasia).  Scoring of the histologic sections 
yielded a significantly (p < 0.05)  higher score in high-dose lambs (3.19) than either control (0.07) or 
low-dose group (0.86) (Figure 3). 
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Immunohistochemistry 
Control lambs lacked staining for RSV antigen while all low-dose and high-dose lambs had cells with 
immunoreactivity for RSV antigen present in areas of consolidation.  Antigen was present in 
epithelial cells lining alveoli and bronchioles and within the cytoplasm of occasional macrophages.  
Scoring of the histologic sections yielded both a higher overall score per animal as well as a greater 
number of total fields with immunoreactive cells per animal in the high-dose group (Figure 4). 
Virus Isolation 
All samples except one high-dose lamb were negative by plaque assay and immunofluorescence.  The 
single animal had 10 plaques by viral assay and 1 by fluorescence.  By comparison, a 1000-fold 
dilution of filtered RSV yielded 1600 plaques.  
RT-qPCR 
Lung homogenates from each animal were assessed by RT-qPCR for relative mRNA levels.  Control 
animals and the one high-dose animal that expelled the inoculum lacked expression of RSV mRNA 
by RT-qPCR.  The high-dose group had significantly higher values than the control or low-dose 
group for MIP-1α (Figure 5).  Additionally, lung samples from each animal were assessed for bovine 
RSV (bRSV) and all animals lacked signal indicating that the lambs did acquire bRSV infection 
naturally. 
Discussion 
Intranasal inoculation with the M37 strain of RSV yielded dose-dependent clinical expiratory effort 
scores, gross lesions, histologic lesions, and altered immune gene expression as assessed by RT-
qPCR in infected lambs.  Because this same viral strain can induce clinical signs in normal adult 
human subjects (17), infection in lambs allows mechanistic investigations that could improve 
understanding of RSV disease in humans.  Also, the model could be used for assessment of 
therapeutic compounds developed specifically for human strains of RSV. 
45 
 
While immune and inflammatory genes explored were not exhaustive, those chosen have been 
reported to be altered in human disease and include: TNF-α, IL-6, IL-8, MIP-1α, RANTES, MCP-1α, 
and limited IFN-γ (22-24).  Also, we have assessed a broad range of these genes in term lambs 
infected with RSV A2 strain and identified mRNA increases in IFN-γ, IL-8, MCP-1α, and 
programmed cell death ligand 1 (PD-L1), and decreases IFN-β, IL-10, and TGF-β (25).  The results 
of this study showed an increase in MIP-1α mRNA levels.  Additionally, while IL-8 was not 
statistically elevated in infected animals, control animals completely lacked signal while high-dose 
animals all had detectable signal.  There was a statistically nonsignificant trend of increased 
expression of RANTES, MCP-1α, and IFN-γ in the high-dose group.  Previous studies in lambs have 
shown limited changes in these chemokines while marked changes in these chemokines have been 
reported in RSV-infected infants (22, 25).  Limited sample sizes (n of 2 or 3) in this study may 
underestimate significant differences between groups.  Also, a lack of increased TNF-α or IL-6 in this 
study could be due to the sampling time point.  We chose day 6 p.i. as previous studies have shown 
this to be a good time point for peak gross and histologic lesions, while increases in TNF-α or IL-6 
tend to occur early in the course of disease (day 3 p.i.) in lambs infected with A2 (25). 
Viral load as assessed by RT-qPCR has shown to peak at day 6 p.i. in our previous studies in lambs 
(19).  By RT-qPCR we had no detectable RSV mRNA in control lambs while all infected lambs had 
measureable RSV mRNA levels.  Plaque assay identified virus at a high level in lambs from the pilot 
study and one animal in the intranasal study.  Day 6 p.i. termination point was selected because it 
provides time to collect additional clinical data and allows time for development of peak gross and 
histologic lesions as well as increased levels of viral mRNA.  For example, increased expiratory effort 
was first detected at day 1 and worsened by day 5 and 6.  Earlier time points may be better for M37 
virus isolation as shown in studies in mouse and cotton rat models where RSV replication often peaks 
at day 3 and 4 p.i. (26, 27). 
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Previous work in our lab with the RSV A2 strain yielded significant changes in body temperature but 
did not yield the marked increased expiratory effort or as extensive gross lesions as observed in this 
study (19).  Differences between this study and the A2 study include a 10-fold higher initial viral titer 
of M37 (in the high-dose group) and intranasal versus intrabronchial inoculation.  The intranasal route 
of inoculation used with M37 in this study may be more reflective of natural infection than 
intrabronchial inoculation as used in our A2 studies.  Also, intranasal inoculation avoids sedation 
which alters airflow and breathing as well as the inherent risk, albeit small, involved in any sedation 
technique.  The drawback is that even small changes in head or body position, overall animal sizes, 
and natural variations in upper respiratory physiology can yield a more variable distribution of virus 
to the lung, and thus a very different pattern of gross and histologic lesion distribution.  Overall, in 
this study there was a more diffuse pattern of lesions as compared to previous studies employing 
intrabronchial inoculations with a fiberoptic bronchoscope or intratracheal inoculation (15, 19).  
Studies to verify the greater virulence of M37 versus A2 among different inoculation methods would 
strengthen this model. 
Route of inoculation (nebulized, intranasal, intratracheal, intrabronchial), viral dose and dilution, as 
well as lamb factors such as vendor source, colostrum deprivation, preterm birth, or age at inoculation 
can all be adjusted with the goal to create low cost, manageable, reproducible large animal models of 
moderate and severe RSV disease.  The data here demonstrate the capacity of a human clinical isolate 
of RSV used for human trials to replicate and cause disease in lambs.  The Memphis 37 strain of RSV 
can be used in lambs to produce moderate respiratory disease and has the potential to be a model of 
more severe disease than the A2 strain.  Further investigation of these viruses in direct comparison is 
needed to isolate differences in disease dynamics between the two strains. 
Overall, lambs closely parallel human infant disease characteristics in clinical course, gross and 
histologic lesions, and inflammatory cytokine profile at key time points in disease.  Also, lambs can 
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be born preterm (90% gestation) and survive for experimentation which allows assessment of RSV 
infection in preterm lung.  Further exploration at multiple time points and expansion of data points 
can be pursued not only to better understand the disease, but to assess response to novel therapeutics 
or prophylactics in this model of disease.  This study strengthens the lamb model by exhibiting 
infection and disease with another human strain of RSV. 
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Tables 
Table 1. Primer and probe sequences used for RT-qPCR, 5’ to 3’ 
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd:
Rev:
Probe:
IFNb
IFNg
TNFa
TGFb
MCP1a
MIP1a
RANTES
GCTCTTAGCAAAGTCAAGTTGAACGA
TGCTCCGTTGGATGGTGTATT
6FAM-ACACTCAACAAAGATCAACTTCTGTCATCCAGC
M37 
hRSV
CCSP
SP-A
IL-6
IL-8
IL-10
CAG CCC TGA CGA AGA CAT GA 
GGG TGT CTA CCA GCG TCT TCA 
6FAM-AGA GGC AAC AAG TCA G-MGBNFQ
TGA CCC TTA TGC TCC TCT GGA T
GGG CTT CCA AGA CAA ACT TCC T 
CGTTGTTGGAATCGAAGCAA
6FAM-ACCACAGCTCTTTCCAGGAGCTACA-TAMRA
GCTGCTCCTGGTGATGACTTC
GGTGGTGTCATTTTTGAAATCTTCT
6FAM-CTTTCCCTACCCCGGGTCCCCTG-MBGNFQ
TTCCAAGCTGGCTGTTGCT
TTGACAGAACTGCAGCTTCACA
6FAM-CCGCTTTCCTGCTCTCTGCAGCTC-TAMRA
6FAM-CAAGGGCCAGGGTTCTTACCGGAA-TAMRA
GTCGGAAATGATCCAGTTTTACCT
GTCAGGCCCATGGTTCTCA
6FAM-AGGAGGTGATGCCACAGG-MGBNFQ
TGGTTCTCCTGCTGTGTTTCTC
6FAM-TGG CTT CTG GCC TCG AGT GCG -TAMRA
TGGAGGACTTCAAAAGGCTGAT
GATGGCTTTGCGCTGGAT
6FAM-CAAATTCCGGTGGATGATCTGC-TAMRA
CAACCTGGGACACCCAGAAT
TCTCAAGGAACGTTGCGAAGT
6FAM-CACCACGCCCTGCT-MGBNFQ
TGTGTTCGTCAGCTCTACATTGAC
TAGCCCTTGGGTTCGTGAAT
6FAM-TCCAGCCCAGGTCCTTCCGGA-TAMRA
GCTGTGATTTTCAAGACCATCCT
GGCGTCCTGGACCCATTT
6FAM-AAAGAGTTTTGTGCAGACCCCAACC-TAMRA
CAGCAGCCAGTGCTCCAA
ACCTGCCGGCCTTTTTTG
6FAM-CCTGGTGTCATCTTCCAGA-MGBNFQ
TGCTTCTGCCTCCCCATATG
GGGCGGGAGATATAGGCAAA
 
  
 Figures 
Figure 1. Clinical data of lambs infected with Memphis 37 human respiratory syncytial 
virus 
Lambs receiving the high-dose 
effort score than control or low
score was assessed as follows: 0
sec, slight abdominal effort; 3 =
over the study period was significantly lower for the high
group. 
Figure 2.  Representative gross lesions and scoring of lesions caused by M37 hRSV in 
lambs 
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(108 PFU/mL) of virus had a significantly higher clinical expiratory 
-dose lambs on days 5 and 6 by two-way ANOVA.  Expiratory effort 
 = no effort; 1 = first detectable prolonged exhale;
 prolonged to >3 sec, hard abdominal effort.  Cumulative weight gain 
-dose group than either control or low
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 Figure 2, cont. 
A. Control lamb lung lacking lesions B. Low
High-dose (108 PFU/mL) lamb lung with severe lesions (Arrows indicate lesions) D. Lesion scores.  
The scoring scale is based on percen
70-100% = 4.  Lesion score in the high
low-dose group, low-dose score is significantly higher than control group; ANOVA, followed 
Tukey’s, P < 0.05. 
 
Figure 3.  Representative histologic lesions and scoring of lesions caused by M37 hRSV 
in lambs 
 
A. Control lamb lung with normal alveoli and bronchioles, 20X magnification. 
with characteristic inflammation including neutrophils and sloughed epithelia cells in bronchioles and 
alveolar septa infiltrated by macrophages, lymphocytes, and fewer neutroph
(arrow), 20X. C. Histologic lesion sco
than either control group or low
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ils with syncytial cells 
res; the histologic score of the high-dose is significantly higher 
-dose group; ANOVA, followed by Tukey’s, P < 0.05. 
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 High-dose lamb 
 
 Figure 4.  Representative immunohistochemistry  (A and B) and scoring of antigen 
immunoreactivity  (C and D) in lambs infected with M37 hRSV
A. Control lamb lung (20X). B. Lung from a lamb receiving high
intracellular staining (20X). C. Total number of fields with immunoreactivity for RSV antigen/animal
for which 20 (10X) fields were assessed for each lung slide.  Each slide contained 2 sections (minimal 
of 1 cm x 1 cm dimension) of lung from a lobe; all 7 lobes of each animal were examined.  The low
dose and high-dose groups were significantly different
followed by Tukey’s, P < 0.05. D. Slides scored by number of positive cells/field.  The high
group had a significantly higher score than the control group; ANOVA, followed by Tukey’s, P < 
0.05. 
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Figure 5.  RT-qPCR results for all targets
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Figure 5, cont.   
M37 mRNA was present in all infected animals and none of the controls.  mRNA levels were 
significantly higher in lambs receiving the high-dose of M37 than either control or low-dose group for 
interferon gamma, interleukin 10, monocyte chemotactic protein, macrophage inflammatory protein 
and surfactant protein A, as indicated by **.  One way ANOVA, followed by Tukey’s method, 
p<0.05.  
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CHAPTER 3: HUMAN RESPIRATORY SYNCYTIAL VIRUS MEMPHIS 
37 GROWN IN HEP-2 CELLS CAUSES MORE SEVERE DISEASE 
THAN VIRUS GROWN IN VERO CELLS 
 
Rachel J. Derscheid1, Albert van Geelen1, Jack M. Gallup1, Tomas Cihlar2, Mark R. Ackermann1 
1Department of Veterinary Pathology Iowa State University College of Veterinary Medicine, 2Gilead 
Inc. 
Abstract 
Respiratory syncytial virus (RSV) is ubiquitous among populations worldwide and is the most 
common cause of bronchiolitis in infants and young children.  In a small percentage of these 
individuals RSV will cause severe and even fatal disease.  To better understand the pathogenesis of 
severe disease and to develop therapies unique to the less-developed immune infant immune system, 
a model of infant disease is needed.  The neonatal lamb pulmonary development and physiology is 
close to that of humans and sheep are susceptible to ovine, bovine, and human strains of RSV.  In 
pilot studies using the Memphis 37 (M37) strain of RSV in young lambs, Vero-grown virus only 
caused disease if inoculated bronchoscopically, while HEp-2 grown virus elicited a robust clinical 
response and pathology with multiple less invasive inoculation methods.  RSV grown in African 
green monkey cells (such as Vero) has a truncated attachment G glycoprotein as compared to that 
grown in HEp-2 cells.  We hypothesized that virus grown in HEp-2 cells would cause more severe 
clinical symptoms as well as cause more severe pathology.  Lambs were infected by two different 
delivery methods with either Vero-grown or HEp-2-grown virus to compare viral infection and 
disease severity.  HEp-2 lambs had higher viral mRNA levels as well as greater clinical disease 
(expiratory effort and tachypnea), greater viral antigen distribution, and more extensive gross and 
histologic lesion scores.  
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Introduction 
Respiratory syncytial virus (RSV) is a Paramyxovirus in the subfamily Pneumovirinae that is 
ubiquitous, causing a range of respiratory disease in infants to the elderly (1, 2).  Clinical 
manifestations primarily occur in infants, young children, the elderly, or the immunocompromised, 
and the greatest morbidity and mortality occurs in infants and young children with an estimated 33.8 
million cases per year of RSV lower respiratory disease in children under 5 years of age (2, 3).  The 
immune systems of infants and young children have responses that sometimes differ from adults; 
however, most animal models of disease have been developed in fully mature animals.   
Perinatal lambs provide an animal model of RSV with a less-mature immune system than adult sheep 
and the lamb has similar lung development and structure to humans.  Rodents are commonly used to 
study RSV infection in vivo; however, rodents have post-natal alveolarization (the final stage of lung 
development) that differs from humans and lambs in which this step occurs prenatally (4, 5).  Also, 
instead of a simple bifurcation into two lung lobes that is present in rodents, sheep have branching 
into multiple lobes like humans which is important for distribution of virus during inoculation, for 
delivery of possible therapies, and respiratory function.  Lung epithelium lining airways and alveoli 
also has an integral role in RSV infection as the bronchiolar epithelium is an active site of RSV 
replication and epithelia contribute to immunity (6).  Lamb lung bronchiolar epithelia have type II 
pneumocytes and Clara cell numbers similar to that of human infants (7) and a similar maturation 
pattern as humans (8).  Also, ovine lung epithelia have similar innate immune responses (e.g., 
production of surfactant proteins and defensins) to human lung (9-11).  Sheep are naturally 
susceptible to RSV and develop disease experimentally when experimentally inoculated with bovine 
RSV or human RSV (12, 13).  Also, preterm lambs can survive at late gestation (roughly 90% 
gestation) and be used for experimental RSV infection (12).  These features make sheep a very 
attractive model for human infant RSV infection. 
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The G glycoprotein is a transmembrane protein embedded in the viral envelope and also occurs as a 
secreted protein (14-17). The G protein is heavily glycosylated through post-translational 
modification in the endoplasmic reticulum and Golgi apparatus (18, 19).  G protein attachment to host 
cell membrane causes a structural change in the fusion protein (F), allowing the virus to incorporate 
its envelope into the host cell membrane (20).  The secreted form of the G protein is involved in 
immune modulation and evasion (17, 21).  While it is not essential for viral replication or infection, 
virus lacking G protein is attenuated (22, 23).  Human strains of RSV replicate in Vero cells; 
however, RSV grown in Vero cells produces a truncated attachment G glycoprotein that is 
approximately 55 kDa rather than 90 kDa (24).  Early in vitro studies that identified the G protein 
reported different sizes, likely due to the use of African green monkey cell lines versus other cell lines 
(14, 25).  Ultrastructurally, RSV viral inclusions in Vero cells differ from those in HeLa or other cell 
lines, and syncytia are reportedly fewer (26, 27).   
Based on our previous findings as well as in vitro studies comparing Vero-grown RSV to virus grown 
in other cell lines including a truncated G glycoprotein when RSV is grown in Vero cells, we 
hypothesized that HEp-2-grown RSV would cause more severe disease as evidenced by clinical 
disease, gross and histologic lesions, and viral replication.  This was tested by infecting neonatal 
lambs through two different inoculation routes using virus grown in each of the two cell types. 
Materials and Methods  
Experimental Design 
Animal use and experimental procedures were approved by Iowa State University’s Animal Care and 
Use Committee.  
Nebulized RSV grown in Vero cells  
Neonatal lambs (2-5 days of age) were randomly assigned to five groups: a day 3 control group (n = 
2), day 3 infected (n = 1), day 6 infected (n = 2), day 10 control (n = 2), or day 10 infected (n = 2).  
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Infected lambs were inoculated with 1 x 106 PFU/lamb in 2 mL DMEM, control lambs received 3 mL 
DMEM without virus for 10 minutes/lamb.  Clinical features (heart rate, respiratory rate, temperature, 
cough, wheeze, expiratory effort, ocular and nasal secretions) were recorded daily and lung tissues 
were collected six days post-inoculation (p.i.).  Expiratory effort (e.g., forced expiratory effort; 
abdominal effort) was scored by: 0 = no expiratory effort; 1 = earliest detection of increased 
expiratory effort; 2 = moderate effort, observed without picking up lamb 3 = hard abdominal effort 
with nostril flaring.   Wheeze was also scored on a scale in which:  0 = no wheeze; 1 = earliest 
detectable wheeze by auscultation; 2 = audible wheeze in all lung fields by auscultation; 3 = wheeze 
audible without stethoscope.  Animals were euthanized by sodium pentobarbital overdose 
(Beuthanasia, Schering Plough Animal Health, Union, NJ) on day 3, 6, or 14 p.i.  Lung tissues from 
one control and two infected lambs on day 3 p.i., two infected lambs on day 6 p.i., and two infected 
lambs and one control on day 10 p.i.  
Intranasal Inoculation of RSV grown in Vero and HEp-2 cells and Nebulized RSV grown in HEp-2 
cells   
Neonatal lambs (2-5 days of age) were randomly assigned to four groups, a control group (n = 4), 
intranasally-inoculated Vero-grown M37 RSV (n = 4), intranasally-inoculated HEp-2-grown M37 
RSV (n = 4), or nebulized HEp-2-grown M37 RSV (n = 5).  Each lamb inoculated intranasally 
received 2 mL/nostril of 1 x 107 PFU/mL inoculum administered via a syringe attached to a mucosal 
atomization device (MAD) (Wolfe Tory Medical, Inc., Salt Lake City, UT, USA).  Control lambs 
were inoculated intranasally with 2 mL/nostril cell growth media.  Lambs receiving nebulized RSV 
grown in either Vero cells or HEp-2 cells received 3 mL of 1 x 106 PFU/mL nebulized with a Jet 
Nebulizer (VixOne, Invacare) at 32 PSI (Phillips Compressor) for 10 minutes.  Six lambs received 
RSV grown in Vero cells while five lambs received RSV grown in HEp-2 cells.  Viral inocula were 
provided by Meridian LifeScience (Memphis, TN, USA).  Lambs were given daily antibiotics 
((Ceftiofur, Pfizer, New York, NY), 1-2 mg/kg, intramuscular) to prevent secondary bacterial 
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infection.  Lambs were monitored daily for clinical signs of respiratory disease and overall health.   
Expiratory effort (e.g., forced expiratory effort; abdominal effort) was scored by: 0 = no expiratory 
effort; 1 = earliest detection of increased expiratory effort; 2 = moderate effort, observed without 
picking up lamb 3 = hard abdominal effort with nostril flaring.  Wheeze score was 0 = no wheeze; 1 = 
earliest detectable wheeze by auscultation; 2 = audible wheeze in all lung fields by auscultation; 3 = 
wheeze audible without stethoscope.  Animals were euthanized by sodium pentobarbital overdose on 
day 6 p.i.  
Post-mortem 
After euthanasia the thorax was opened, lungs were removed, and gross lesions were scored and 
photographed ex vivo.  Tissue samples were collected from all animals with the same protocol. 
Briefly, multiple samples from each lobe were snap frozen in liquid nitrogen for RT-qPCR with 
pooling from proximal and distal regions of the lobe for each sample, two samples at similar levels of 
each lobe were placed in tissue cassettes and put in 10% neutral-buffered formalin for histological 
and immunohistochemical analysis.   
Fluorogenic one-step real-time quantitative PCR (RT-qPCR) 
Whole vials of right and left cranial, right and left middle, and accessory lobes snap frozen from 
lambs posted at 6 days p.i. were homogenized in TRIzol (Invitrogen, Carlsbad, CA, USA), then 
pooled for each animal to create a composite slurry.  RNA isolation continued per manufacturer’s 
instructions (Invitrogen), followed by DNase treatment (Ambion, TURBO DNase, Austin, TX, USA), 
then diluted 1:10 with a combination of RNaseOUT (Invitrogen) and nuclease-free water 
(Invitrogen).  Spectrophotometry (NanoDrop, Thermo Scientific, Waltham, MA, USA) was used to 
assess each sample for purity and quantity.  Fluorogenic one-step RT-qPCR was carried out using 
One-Step Fast qRT-PCR Kit master mix (Quanta BioSciences, Gaithersburg, MD, USA) in a 
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GeneAmp 5700 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA) employing 
PREXCEL-Q for all set up calculations (28).  Primer and probe sequences (Table 1) have been 
previously used in our lab.  All sequences were generated using ABI Primer Express 2.0 software.  
All samples were diluted to achieve a final RT-qPCR concentration of 0.7844 ng/µL.  Each sample 
was assessed in duplicate and each target gene amplification Cq converted to a relative quantity (rQ) 
based on the standard curve and using the following equation: rQ = 10((Cq-b)/m), where Cq is the target 
quantification cycle, and b and m are the y-intercept and slope, respectively, from the Stock I-derived 
standard curve for each target (28). 
Gross Lesion Evaluation and Scoring 
After removal of lung, percentage parenchymal involvement was estimated for each lung lobe.  
Percentages were converted to a scale using the following formula: 0% = 0, 1-9% = 1, 10-39% = 2, 
40-69% = 3, 70-100% = 4.  Group averages were calculated for the gross lesion score. 
Histologic Evaluation and Scoring 
Lung histologic score was determined by determining percent consolidation, conversion to a 
consolidation scale used by our laboratory previously (13): 0% consolidation = 0, 1-9% consolidation 
= 1, 10-39% consolidation = 2, 40-69% consolidation = 3, 70-100% consolidation = 4.  Group 
averages were calculated for the alveolar consolidation score. 
Immunohistochemistry 
Immunohistochemistry for RSV antigen was performed on paraffin-embedded tissue as described 
previously (13) with the following variations: instead of  Pronase E antigen retrieval, heated buffer 
antigen retrieval was performed in TE, pH 9.0 in a pressure cooker device (Decloaking Chamber™ 
Plus, Biocare Medical, Concord, CA) using the factory default program lasting approximately forty 
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minutes with a peak temperature of 125°C attained in approximately 18 minutes followed by a 30 
second hold.  Subsequent machine cool down to 80°C required approximately 22 minutes and was 
followed by 5 minutes in an ice bath.  Primary polyclonal goat anti-RSV antibody 
(BioDesign/Meridian, San Ramon, CA, USA) was applied for 2 hours at room temperature at a 
concentration of 1:300 instead of 1:50 as previously described.  Color was developed with Nova Red 
(Vector, Burlingame, CA, USA), counterstaining with Harris’ hematoxylin, after which slides were 
dehydrated and cover-slipped.  Slides were then assessed for both the number of 10X fields with RSV 
antigen out of 20 for each slide as well as number of immunoreactive cells per 10X field.  The 
number of cells immunoreactive for RSV per field was then given a score according to the following 
scale: 0 = 0, 1 = 1-10, 2 = 11-39, 3 = 40-99, 4 = >100. 
Statistical Analysis 
All analyses were performed using GraphPad Prism 5.  All post-mortem data was assessed with one-
way ANOVA followed by Tukey’s post-test.  RT-qPCR data was log transformed for normality, if 
necessary.  All clinical data was assessed with two-way ANOVA and cumulative weight change was 
additionally assessed with one-way ANOVA followed by Tukey’s post-test. 
Results 
Clinical and post-mortem findings 
There was no significant difference between control lambs and any of the infected groups for any of 
the parameters measured.  There was no significant difference in body temperature or weight gain 
over the course of the study.   
Of the two NeV lambs posted at day 6 p.i., one had a mild cough and mild wheeze, though no gross 
lesions.  Lambs of the NeV group posted at day 3 and 14 p.i. lacked clinical signs. There was no 
significant difference from control in clinical symptoms when analyzed by two-way ANOVA.   
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Two of 4 lambs inoculated intranasally with HEp-2-grown virus (INH) developed increased 
expiratory effort with one of the lambs progressing to grade 3 expiratory effort and clinical illness as 
evidenced by a reluctance to move and lethargic attitude.  The average expiratory effort score was 
significantly higher than the control on day 6 p.i. (Figure 1).  These two clinically symptomatic 
lambs had significant gross lesions characterized by large, well-delineated areas of dark red to red-
gray discoloration and associated depressed parenchyma (atelectasis); a third lamb had very small, 
punctate areas of similar discoloration and the last lamb had no gross changes.  Gross lesions affected 
a larger portion of the cranial and middle lobes than the caudal or accessory lobes.   
Two of 4 INV lambs developed a grade 1 wheeze.  Group wheeze score was never significantly 
different from control.  These two lambs had small but distinct areas of slightly depressed dark red-
gray discoloration.   
Of the 5 NeH lambs, one developed a grade 1 expiratory effort and one developed a mild cough 
(coughing once per five minutes or less frequently).  All 5 of these lambs had dark red to red-gray 
multifocal, pinpoint to confluent foci of consolidation in most if not all lung lobes.  The average gross 
percentage score of the INH group was significantly higher than control lambs or INV lambs (Figure 
2) at 6 days p.i.  
Histopathology  
Lambs inoculated intranasally that developed gross lesions had histologic lesions characterized by 
multifocal to confluent foci of cellular infiltration that filled or partially filled bronchioles and alveoli 
and expanded the alveolar interstitium consistent with RSV infection reported previously in lambs 
(16, 19).  Bronchioles and alveoli contained moderate to abundant amounts of sloughed, degenerate 
epithelial cells and neutrophils.  Large epithelial syncytial cells were present within multifocal 
bronchioles.  Pulmonary epithelium lining affected airways was low to plump cuboidal with oval, 
vesiculate nuclei (type II pneumocyte hyperplasia).  The INH group tended to have smaller, more 
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dispersed lesions with a similar cellular population, and presence of fewer epithelial syncytia.  
Scoring of the histologic sections yielded a significantly higher score in both the NeH and INH lamb 
froups than the control or either of the Vero-inoculated group at 6 days p.i. (Figure 3). NeV lambs at 
3 and 14 days p.i. lacked histologic lesions compatible with RSV. 
Immunohistochemistry 
Control lambs and NeV lambs lacked staining for RSV antigen while infected lambs had cells 
immunoreactive for RSV antigen present in or near areas of consolidation (Figure 4).  Antigen was 
present in epithelial cells lining alveoli, bronchioles and within the cytoplasm of occasional 
macrophages.  Scoring of the histologic sections yielded a higher overall score per animal in INH 
compared to control or INV groups, and a higher overall score in NeH versus control or INV (Figure 
5).  The NeH group had a higher number of total fields per animal with RSV antigen compared to 
control or either Vero-infected group (Figure 5) at 6 days p.i.  NeV lambs at 3 and 12 days p.i. lacked 
viral antigen.     
RT-qPCR 
Lung homogenates from each animal from 6 days p.i. were assessed by RT-qPCR for relative mRNA 
levels of M37 RSV (M37).  Control, INV, INH, and NEH tissues were also assessed for Clara cell 
secretory protein (CC10), surfactant protein A (SP-A), interleukin 6 (IL-6), interleukin 8 (IL-8), 
interleukin 10 (IL-10), macrophage inflammatory protein (MIP-1α), monocyte chemotactic protein 
(MCP1α), tumor necrosis factor alpha (TNF-α), transforming growth factor beta (TGF-β), interferon 
beta (IFN-β), interferon gamma (IFN-γ), and regulated on activation normal T-cell expressed and 
secreted (RANTES) (Figure 6).  NeV tissues were not assessed for additional targets at the time of 
initial study and tissues were not available for retrospective analysis.  Control animals and both NeV 
lambs lacked expression of RSV mRNA by RT-qPCR while significant differences in viral levels 
were present between all groups except the two HEp-2 inoculated groups.  CC10 levels were 
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significant higher in NeH than either control or INH.  TNF-α was significantly higher in INV lambs 
than either control or INH.   
Discussion 
HEp-2-grown respiratory syncytial virus (RSV) caused disease when inoculated intranasally or when 
nebulized, as opposed to only intranasal Vero-grown virus causing disease in neonatal lambs.  
Additionally, lower levels of RSV mRNA were detected with INV than with either method of 
inoculation with HEp-2.  With previous reported differences in the G glycoprotein (24), a reasonable 
cause of decreased RSV infection and disease severity is decreased attachment of the virus to 
epithelial cells.  This finding is significant for experimental inoculations of RSV and may explain 
some of the variability seen in RSV disease severity in animal models and experimental human 
subjects.   
Variations in clinical features were identified.  The difference in respiratory rates was not attributed to 
disease as it did not correlate to any other findings.  M37 caused an increased expiratory effort in 
some lambs and this may either increase or decrease respiratory rate, causing tachypnea with less 
expiratory effort and actually slowing respirations with marked (grade 3) effort.  Coughing is rarely 
seen, but a wheeze sometimes accompanied the expiratory effort, although the wheeze is usually mild 
and detectable only by auscultation.  On day 6 p.i., the increased expiratory effort in the INH group 
was significantly higher than control lambs, which was consistent with a previous experiment using 
M37.     
TNF-α is an acute-phase, proinflammatory cytokine that has been shown to be increased in 
nasopharyngeal secretions at the time of hospitalization for RSV infection in infants (29).  In our 
previous studies, an increase in TNF-α was shown to occur in infected lambs at day 3 p.i., but it 
returned to control levels by day 6 p.i. (30).  The previous kinetics as well as the lack of clinical signs 
and minimal lesions typical of RSV are evidence that the increased TNF-α in the INV group is likely 
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not due to RSV infection.  While lambs are maintained on antibiotics, there is always a possibility of 
bacterial infection, either local or systemic.  No signs of bacterial pneumonia were present.  The 
CC10 level is difficult to interpret, as initial death of Clara cells results in release of CC10; 
alternatively, CC10 can be upregulated by stressed cells and a reduction in Clara cells (due to viral 
damage) can decrease overall production of CC10.  Additionally, Clara cell responses tend to be 
highly localized, so differences between Clara cell numbers in sample lobes can affect CC10 levels as 
well.  Despite these caveats, the increase in CC10 in the NeH group is intriguing as RSV can infect 
Clara cells; however, the extent to which RSV infects Clara cells has not been fully established in 
humans or lambs.  Further characterization of Clara cell infection by RSV and CC10 
release/production throughout the course of RSV infection may be possible through laser capture 
microdissection.  There was a strong trend of the INH group for increased mRNA of MCP1α, MIP1α, 
and IL-8.  Of the four lambs, one was less affected by disease than the other 3, which increased the 
variation in the group average.  While every effort is made to normalize inoculation between lambs, 
the intranasal method of inoculation may allow for some swallowing of viral media and this may 
account for part of the difference between lambs in the group. Nonetheless, all four lambs did get 
infected and three had moderate to severe lesions. 
An additional interesting finding that could be important in further model development was the 
distribution of lesions in intranasal versus nebulized HEp-2-grown virus.  Respiratory syncytial virus 
mRNA was detected by RT-qPCR in all lambs inoculated with HEp-2 grown virus, but both the 
highest and lowest amounts were present in the intranasally-inoculated group.  Thus, while RSV 
mRNA was higher as were consolidation, histologic, and immunohistochemical scores in the 
intranasally-inoculated lambs, viral mRNA present at 6 days p.i. in the nebulized group was more 
consistent.  Additionally, while a greater number of cells were immunoreactive for RSV antigen in 
the intranasally-inoculated lambs, a greater portion of microscopic fields contained RSV antigen in 
the nebulized lambs.  The nebulization process may cause some damage to the virus and may 
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contribute to the decreased infectivity of the Vero-grown virus. Also, nebulization likely delivers 
more virus at the alveolar level which in-turn may allow uptake by macrophages and perhaps even 
type II cells resulting in some viral replication but less so than that which can occur in type II and 
Clara cells of the bronchioles.  No difference in hardiness of Vero-grown RSV (compared to HEp2 
grown RSV) has been reported; therefore, while a decrease in virus delivered to airways by 
nebulization may occur, no difference in amount of live virus between the strains delivered to airways 
is expected. 
In summary, HEp-2 grown M37 hRSV inoculated by intranasal or nebulized methods causes 
increased disease in neonatal lambs when compared to Vero-grown virus, and this is likely due to the 
truncation of the RSV G attachment protein that occurs when RSV is grown in Vero cells but not 
HEp-2 cells.  Additionally, nebulized virus yields a different pattern of gross and histologic lesions 
and may cause more consistent infection.  Also, perinatal lambs are a useful model of perinatal 
infection using intranasally-inoculated or nebulized HEp-2 grown RSV. 
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Tables 
Table 2. Primer and probe sequences used for RT-qPCR, 5’ to 3’ 
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd: Fwd:
Rev: Rev:
Probe: Probe:
Fwd:
Rev:
Probe:
IFNb
IFNg
TNFa
TGFb
MCP1a
MIP1a
RANTES
GCTCTTAGCAAAGTCAAGTTGAACGA
TGCTCCGTTGGATGGTGTATT
6FAM-ACACTCAACAAAGATCAACTTCTGTCATCCAGC
M37 
hRSV
CCSP
SP-A
IL-6
IL-8
IL-10
CAG CCC TGA CGA AGA CAT GA 
GGG TGT CTA CCA GCG TCT TCA 
6FAM-AGA GGC AAC AAG TCA G-MGBNFQ
TGA CCC TTA TGC TCC TCT GGA T
GGG CTT CCA AGA CAA ACT TCC T 
CGTTGTTGGAATCGAAGCAA
6FAM-ACCACAGCTCTTTCCAGGAGCTACA-TAMRA
GCTGCTCCTGGTGATGACTTC
GGTGGTGTCATTTTTGAAATCTTCT
6FAM-CTTTCCCTACCCCGGGTCCCCTG-MBGNFQ
TTCCAAGCTGGCTGTTGCT
TTGACAGAACTGCAGCTTCACA
6FAM-CCGCTTTCCTGCTCTCTGCAGCTC-TAMRA
6FAM-CAAGGGCCAGGGTTCTTACCGGAA-TAMRA
GTCGGAAATGATCCAGTTTTACCT
GTCAGGCCCATGGTTCTCA
6FAM-AGGAGGTGATGCCACAGG-MGBNFQ
TGGTTCTCCTGCTGTGTTTCTC
6FAM-TGG CTT CTG GCC TCG AGT GCG -TAMRA
TGGAGGACTTCAAAAGGCTGAT
GATGGCTTTGCGCTGGAT
6FAM-CAAATTCCGGTGGATGATCTGC-TAMRA
CAACCTGGGACACCCAGAAT
TCTCAAGGAACGTTGCGAAGT
6FAM-CACCACGCCCTGCT-MGBNFQ
TGTGTTCGTCAGCTCTACATTGAC
TAGCCCTTGGGTTCGTGAAT
6FAM-TCCAGCCCAGGTCCTTCCGGA-TAMRA
GCTGTGATTTTCAAGACCATCCT
GGCGTCCTGGACCCATTT
6FAM-AAAGAGTTTTGTGCAGACCCCAACC-TAMRA
CAGCAGCCAGTGCTCCAA
ACCTGCCGGCCTTTTTTG
6FAM-CCTGGTGTCATCTTCCAGA-MGBNFQ
TGCTTCTGCCTCCCCATATG
GGGCGGGAGATATAGGCAAA
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Figure 2.  Representative gross lesions of lambs inoculated with respiratory syncytial 
virus (RSV) 
 
Arrows indicate viral lesions.  The INH group had significantly more gross involvement than control, 
INV, or NeV, p<0.05.   
Figure 3.  Representative histologic lesions (10X magnification) of lambs inoculated 
with respiratory syncytial virus (RSV) 
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 Figure 3, cont. 
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Figure 4.  Immunohistochemical staining for RSV antigen 
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 Figure 4, cont. 
Representative immunohistochemical staining of lambs inoculated with respiratory syncytial virus 
(RSV), 10X magnification.  Viral antigen is widely dispersed and staining is intense in lung of lambs 
infected with RSV grown in HEp
little or no antigen.  
Figure 5.  RSV immunohistochemical s
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 Figure 6.  Relative (RT-qPCR) mRNA levels of respiratory syncytial virus (RSV) and 
immune and inflammatory mediator targets, relative to stan
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Figure 6, cont.  Significant differences between groups are represented by a (*), significance is 
p<0.05.  Clara cell secretory protein (CC10), surfactant protein A (SP-A), interleukin 6 (IL-6), 
interleukin 8 (IL-8), interleukin 10 (IL-10), macrophage inflammatory protein (MIP-1α), monocyte 
chemotactic protein (MCP1α), tumor necrosis factor alpha (TNF-α), transforming growth factor beta 
(TGF-β), interferon beta (IFN-β), interferon gamma (IFN-γ), and regulated on activation normal T 
cell expressed and secreted (RANTES).   
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Rachel J. Derscheid, Albert van Geelen, Jack M. Gallup, Mark R. Ackermann 
Department of Veterinary Pathology Iowa State University College of Veterinary Medicine  
Abstract 
Respiratory syncytial virus (RSV) is the most common cause of infant bronchiolitis, yet there is no 
vaccine or fully satisfactory therapy available, even after more than fifty years of research.  RSV 
vaccine and therapeutic regimen development and disease investigation would benefit from a model of 
neonatal RSV disease, especially one modeling severe disease.  Based on results from previous 
separate studies, we hypothesized that M37 would cause more severe disease than A2 in inoculated 
neonatal (2-5 day old) lambs.  This was tested by inoculating 2-5 day old, colostrum-deprived lambs 
via nebulization with either control media (n = 7), A2 RSV (n = 6), or M37 RSV (n = 6).  Lambs were 
monitored for clinical signs then euthanized at 6 days post infection for assessment of lesions and RT-
qPCR for RSV and innate immune factors.  Differences in disease parameters were minor, with M37 
lambs developing tachypnea and having more diffuse gross lesions, although A2 had more viral 
mRNA present in lung tissue than M37.  We conclude that while M37 can cause disease in perinatal 
lambs, there is little difference between A2 and M37 strain when nebulized at this concentration.   
Introduction 
Respiratory syncytial virus (RSV) causes seasonal respiratory disease in infants and young children 
with disease ranging from mild upper respiratory systems to rare fatalities.  Case estimates range from 
32-64 million per year worldwide (1, 2), with 58,000-125,000 cases requiring hospitalization in the 
United and another 1.5 million treated as outpatients (3).  The case numbers of moderate to severe 
disease are likely under-reported, as in developing countries only 25-30% of cases recommended by 
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WHO guidelines for hospitalization actually get admitted and in other cases diagnostics are not 
pursued (4).  This ubiquitous infantile and childhood disease has no vaccine, despite over fifty years of 
research. 
Stumbling blocks in vaccine development began early, with a vaccine trial in the 1960s leading to 
enhanced disease with natural infection (5).  Further research has been directed at elucidating the 
underlying pathogenesis of enhanced disease as well as developing an efficacious vaccine for neonates 
and children.  Rodent models, especially transgenic mice, have been used to identify a number of 
important factors in RSV disease, such as key genes and innate immune targets.  For example, the 
importance of Toll-like receptor (TLR-4) and CD14 signaling during RSV infection was first 
identified in TLR-4 knockout mice (6) and mice were used in discovering the role of nonstructural 
RSV proteins in mediating disease (7).  Cotton rats have an enhanced disease with vaccination, much 
like the initial human vaccine, although the cellular infiltrate tends to be less eosinophilic and more 
lymphocytic than human infants (8, 9).  Also, these studies are generally performed in adult cotton rats 
as opposed to neonates. 
Rodent models of neonatal RSV disease have some features that do not fully mimic infants.  Rodent 
lungs have a distinctly different branching pattern and different ratios of epithelial cell components, 
lacking submucosal glands and having a higher proportion of Clara cells (~50%) as compared to 
humans (10).  Of specific importance to the neonatal model, rodents begin alveolarization, the final 
stage of lung development, postnatally while humans begin this stage prenatally and continue 
postnatally as do lambs (11, 12).  Additionally, derivation of preterm rodents is difficult since many 
rodents do not survive when born preterm.  Preterm birth is one of the greatest risk factors for severe 
RSV, with premature infants hospitalized for RSV being more likely to have apnea, require 
mechanical ventilation or supplemental oxygen, require admittance to intensive care unit (ICU), and 
have a longer hospital stay than their full-term counterpart (13).  Thus, a model that can be adapted to 
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preterm birth would lead to a better understanding the cellular and immune risk factors and also allow 
preclinical testing of therapeutics for this population. 
Sheep are used as a model for a number of respiratory diseases such as congenital diaphragmatic 
hernia (14, 15), asthma (16, 17), and maternal alcohol consumption during pregnancy (18) as well as 
RSV infection (19-22).  Sheep and humans share a number of upper and lower airway features 
including: nasal lymphoid tissue distribution, alveolar size, submucosal gland type and distribution, 
cartilage distribution, sensory nerves, airway capillary physiology, mast cell distribution, mucus-
secreting cells, numbers of Clara cells in bronchioles, histamine effects, and cough/wheeze response 
(23).  Sheep are susceptible to natural RSV infection, and up to 85 % of sheep have detectable anti-
RSV serum antibody (24). Sheep can be experimentally infected with bovine or human strains of RSV 
and develop disease (19-22, 25).  Lambs are a particularly good model of pulmonary RSV disease in 
infants due to the similar size, alveolar development and other structural, cellular, and physiologic 
features indicated above.  Preterm lambs have increased RSV disease severity compared to full term 
lambs and histopathology of RSV lesions in lambs (and cattle) is similar to that seen in human infants 
(19-21).   
In this study perinatal lambs were inoculated with nebulized hRSV Memphis strain 37 (M37) or 
nebulized hRSV A2 strain.  Previously our group has administered virus (bRSV or hRSV A2 strain) 
intratracheally or intrabronchially (21, 22, 26).  It was our hypothesis that nebulized M37 hRSV would 
produce clinical disease and pathology more severe than nebulized A2 strain hRSV.  Our results 
demonstrate that nebulized M37 causes moderate disease similar to or greater than nebulized A2, but 
has lower mRNA levels of RSV at 6 days p.i.  Additionally, nebulization of RSV may alter the gross 
and histologic lesion pattern of RSV in lambs as compared to other routes of inoculation. 
Materials and Methods 
Experimental Design 
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Animal use and experimental procedures were approved by Iowa State University’s Animal Care and 
Use Committee.   
Colostrum-deprived neonatal lambs (2-5 days of age) were randomly assigned to three groups, a 
control group (n = 7), an hRSV M37 group (n = 6), or an hRSV A2 group (n = 6).  Each lamb received 
3 cc of 6 x 106 plaque-forming units (PFU) (total) RSV grown in either Vero cells or HEp-2 cells 
nebulized with a Jet Nebulizer (VixOne, Invacare) at 32 PSI (Philips Compressor) for 20 minutes.  
Control lambs were inoculated with cell growth media.  M37 viral inocula were grown in HEp-2 cells 
from virus provided by Meridian LifeScience (Memphis, TN, USA).  RSV (A2 strain) was propagated 
in HEp-2 cells (American Type Culture Collection [ATCC], Manassas, VA).  Lambs were given daily 
antibiotics ((ceftiofur, Pfizer, New York, NY) 1-2 mg/kg, intramuscular) to prevent secondary 
bacterial infection.  Lambs were monitored daily for clinical signs of respiratory disease and overall 
health.  Expiratory effort was scored by: 0 = no expiratory effort; 1 = earliest detection of increased 
expiratory effort; 2 = moderate effort, observed without picking up lamb; 3 = hard abdominal effort 
with nostril flaring.  Wheeze was also scored on a scale in which:  0 = no wheeze; 1 = earliest 
detectable wheeze by auscultation; 2 = audible wheeze in all lung fields by auscultation; 3 = wheeze 
audible without stethoscope. Animals were euthanized by sodium pentobarbital (Beuthanasia, 
Schering Plough Animal Health, Union, NJ) overdose on day 6 p.i as this timepoint is when gross and 
histologic lesions peak when inoculated with RSV A2 strain (22). 
Post-mortem 
After euthanasia the thorax was opened, lungs were removed, and gross lesions were scored as 
described previously (22) and photographed ex vivo.  Tissue samples were collected from each lung 
lobe of all animals in the same manner. Briefly, multiple samples from each lobe composed of mixed 
tissue from proximal to distal were snap frozen in liquid nitrogen for RT-qPCR, two samples from 
each lobe were taken at similar levels, placed in tissue cassettes, and put in 10% neutral-buffered 
formalin for histological and immunohistochemical analysis.   
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Fluorgenic one-step real-time quantitative PCR (RT-qPCR) 
Whole vials of right and left cranial, right and left middle, and accessory lobes were homogenized in 
TRIzol (Invitrogen, Carlsbad, CA, USA), then pooled for each animal to create a composite slurry.  
RNA isolation continued per manufacturer’s instructions (Invitrogen), followed by DNase treatment 
(Ambion, TURBO DNase, Austin, TX, USA), then diluted 1:10 with a combination of RNaseOUT 
(Invitrogen) and nuclease-free water (Invitrogen).  Spectrophotometry (NanoDrop, Thermo Scientific, 
Waltham, MA, USA) was used to assess each sample for purity and quantity.  Fluorogenic one-step 
RT-qPCR was carried out using One-Step Fast qRT-PCR Kit master mix (Quanta BioSciences, 
Gaithersburg, MD, USA) in a GeneAmp 5700 Sequence Detection System (Applied Biosystems, 
Carlsbad, CA, USA) employing PREXCEL-Q for all set up calculations (27).  The following targets 
were assessed: M37 RSV (M37), A2 RSV (A2), Clara cell secretory protein (CC10), surfactant protein 
A (SP-A), interleukin 8 (IL-8), interleukin 10 (IL-10), macrophage inflammatory protein (MIP-1α), 
monocyte chemotactic protein (MCP-1α), tumor necrosis factor alpha (TNF-α), interferon beta (IFN-
β), interferon gamma (IFN-γ), and regulated on activation normal T-cell expressed and secreted 
(RANTES).  Primer and probe sequences (Table 1) have been previously used in our lab.  All 
sequences were generated using ABI Primer Express 2.0 software.  All samples were diluted to 
achieve a final RT-qPCR concentration of 0.7844 ng/µL.  Each sample was assessed in duplicate and 
each target gene amplification Cq converted to a relative quantity (rQ) based on the standard curve 
using the following equation: rQ
 
= 10((Cq-b)/m), where Cq is the target quantification cycle, and b and m 
are the y-intercept and slope, respectively, from the Stock I-derived standard curve for each target (27).   
Gross Lesion Evaluation and Scoring 
After removal, percentage parenchymal involvement was estimated for each lung lobe.  Percentages 
were converted to a scale using the following formula: 0% = 0, 1-9% = 1, 10-39% = 2, 40-69% = 3, 
70-100% = 4.  Group averages were calculated for the gross lesion score. 
Histologic Evaluation and Scoring 
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Lung histologic score was based on percent consolidation, with conversion to a consolidation scale 
used by our laboratory previously (22): 0% consolidation = 0, 1-9% consolidation = 1, 10-39% 
consolidation = 2, 40-69% consolidation = 3, 70-100% consolidation = 4.  Group averages were 
calculated for the alveolar consolidation score. 
 
Immunohistochemistry 
Immunohistochemistry for RSV antigen was performed on paraffin-embedded tissue as described 
previously (22) with the following variations: instead of  enzymatic Pronase E antigen retrieval, heated 
buffer antigen retrieval was performed in TE, pH 9.0 in a pressure cooker device (Decloaking 
Chamber™ Plus, Biocare Medical, Concord, CA) using the factory default program lasting 
approximately forty minutes with a peak temperature of 125°C attained in approximately 18 minutes 
followed by a 30 second hold.  Subsequent machine cool down to 80°C required approximately 22 
minutes and was followed by 5 minutes in an ice bath.  Primary polyclonal goat anti-RSV antibody 
(BioDesign/Meridian, San Ramon, CA, USA) was applied for 2 hours at room temperature at a 
concentration of 1:300 instead of 1:50 as previously described.  Color was developed with Nova Red 
(Vector, Burlingame, CA, USA), counterstaining with Harris’ hematoxylin, after which slides were 
dehydrated and cover-slipped.  Slides were then assessed for both the number of 10X fields with RSV 
antigen out of 20 fields for each slide as well as number of immunoreactive cells per 10X field.  The 
number of cells immunoreactive for RSV per field was then given a score according to the following 
scale: 0 = 0, 1 = 1-10, 2 = 11-39, 3 = 40-99, 4 = >100. 
Statistical Analysis 
All analyses were performed using GraphPad Prism 5.  All post-mortem data was assessed with one-
way ANOVA followed by Tukey’s post-test.  All clinical data was assessed with two-way ANOVA 
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and cumulative weight change was additionally assessed with one-way ANOVA followed by Tukey’s 
post-test.  
Results 
Clinical and post-mortem findings 
Respiration rate of the M37 lambs was significantly higher than control lambs on days 4 and 6 p.i. 
(Figure 1).  Three of six (3/6) lambs inoculated with M37 RSV developed a grade 1 or 2 wheeze or 
expiratory effort (i.e., forced expiratory effort; abdominal effort) beginning on day 4 p.i.  Two of six 
(2/6) lambs inoculated with A2 RSV developed a grade 1 wheeze and concurrent grade 1 expiratory 
effort on day 6.  One of the A2-inoculated lambs had a grade 2 expiratory effort before inoculation and 
on day 6 p.i.  There was no significant change in the overall group clinical score for either expiratory 
effort or clinical wheeze, nor any other clinical parameter (rectal temperature or heart rate).  All six 
M37-infected lambs had multifocal to locally extensive dark pink to gray, well-demarcated foci of 
pulmonary consolidation which varied in severity from mild to moderate; 5 of 6 (5/6) A2-infected 
lambs had minimal to moderate lesions similar in nature (Figure 2).  Larger areas were slightly firm to 
rubbery on palpation.  Gross lesion scores (based on percentage of lung parenchyma involved) of the 
M37 group were significantly higher than controls (Figure 2).   
Histopathology  
Infected lambs had multifocal cellular infiltrates composed of neutrophils, macrophages and small 
amounts of cell debris that filled small bronchioles and occasionally adjacent alveoli. Alveolar 
interstitium was multifocally thickened by a cellular infiltrate composed of lymphocytes, neutrophils, 
macrophages, and plasma cells.  There were increased intra-alveolar pulmonary macrophages 
associated with the interstitial infiltrate.  Multifocal bronchioles and nearby alveoli contained moderate 
amounts of sloughed, degenerate epithelial cells and neutrophils.  Large epithelial syncytial cells were 
rarely present within bronchioles.  Scoring of the histologic sections yielded a significantly higher 
score in M37 than control and a higher score in A2 compared to control (Figure 3). 
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Immunohistochemistry 
Slides were assessed for both number of immunoreactive cells/10X field as well as total number of 
10X fields with positive cells (out of 20 fields/slide, 7 slides/animal).  A2 and M37-infected lambs 
both had similar staining which was primarily in bronchiolar epithelium with scattered individual cells 
in alveoli or lining alveolar walls.  A2 lambs had a significantly higher number of positive fields (avg. 
59.5 out of 140) than either control or M37 lambs.  M37 lambs had a significantly higher number of 
fields with immunoreactivity (avg. 24.9 out of 140) than control lambs (Figure 4). 
RT-qPCR 
Lung homogenates from each animal were assessed by RT-qPCR for relative mRNA levels of, M37, 
A2, CC10, SP-A, IL-8, IL-10, MIP-1α, MCP-1α, TNF-α, IFN-β, IFN-γ, and RANTES (Figure 5).  
TNF-α was not detected in any animal; IL-8 was detected in low levels in only two animals; these two 
targets are excluded from Figure 1. Other targets were not significantly different from control. 
Discussion 
Nebulized inoculation of lambs with either Memphis 37 or A2 strain of RSV caused clinical tachypnea 
or wheeze, gross and histologic lung lesions, and detectable RSV mRNA.  Thus, both strains can infect 
lambs with nebulization; differences between the two strains were not observed in this study.  In 
previous experiments in our laboratory M37 delivered intratracheally, by aerosolized particles, or with 
fiberoptic bronchoscope has induced marked increases in expiratory effort as well as extensive gross 
and histologic lesions, and viral replication that we have not observed with A2 (22; chapters 2 and 3 of 
this dissertation).  Nebulization may distribute viral particles to bronchiolar and alveolar locations in 
the lung that favor A2 replication more so than M37.  This is speculative and additional studies will be 
required to test this notion.  Nebulization has some distinct advantages over intratracheal and 
fiberoptic deposition.  First, nebulization provides a more even distribution of virus within the various 
lung lobes while fiberoptic bronchoscope and intratracheal inoculation deposits volumes of virus in the 
cranioventral lobes, and aerosolized particles are larger (roughly 100 µm) and do not reach the lung as 
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readily as nebulized particles (approximately 5 µm).  Also, nebulization provides a finer deposition of 
viral particles onto the lung airway and alveolar air-surface liquid whereas fiberoptic and intratracheal 
deposition flood a region of airways.  This flooding likely overcomes local innate defense mechanisms 
such as the oxidative defense system and innate immune products such as surfactant proteins, 
lactoferrin, defensins, immunoglobulin A, and other molecules with anti-RSV properties.  Finally, 
nebulization may also have advantages for assessment of newly developed anti-RSV drugs.   
While immune and inflammatory genes explored were not exhaustive, those chosen have been 
reported to be altered in human disease and include: TNF-α, IL-6, IL-8, MIP-1α, RANTES, MCP-1α, 
and limited IFN-γ (28-30).  In a previous study of lambs inoculated by fiberoptic bronchoscope with 
A2 strain, increased mRNA levels of IFN-γ, IL-8, MCP-1α, and programmed cell death ligand 1 (PD-
L1), and decreased mRNA levels of IFN-β, IL-10, and TGF-β were observed at day 6 p.i. (31). While 
statistical significance was not reached, there was a trend of decreased RANTES in both the A2 and 
M37 groups.  In vitro studies show that RSV induces RANTES production and that RANTES has 
antiviral activity (32-34).  Conversely, increased RANTES has been shown to contribute to disease 
severity and is associated with post-bronchiolitis wheeze (32, 35, 36).  IL-8 was detected in one A2-
inoculated lamb, but no other lambs on study.  As indicated, fiberoptic inoculation of lambs with A2 
has previously been shown to cause an increase in IL-8 mRNA levels, and in previous unpublished 
studies with M37 IL-8 has been detected at high levels in infected lambs while remaining undetectable 
in control lambs. There was a trend toward increased MCP-1α and MIP-1α, IL-6, and CC10 and 
decrease in RANTES mRNA levels in M37 lambs, while A2 lambs had a trend toward increased IL-6 
and decreased MCP-1α and RANTES.  Previous studies in lambs have shown alterations in mRNA 
levels of RANTES, MCP-1α, and IFN-γ at day 6 p.i., while there are marked changes in these 
chemokines in RSV-infected infants (28, 31).  Previous studies using A2-infected lambs have shown 
an increase in IL-6 at day 3 p.i. (31), but a decrease by day 6.  This is primarily an acute phase 
chemokine, so the increase at day 6 p.i. is either a persistent elevation due to RSV infection or possibly 
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a confounding infection.  As with clinical signs and gross lesions, the differences seen in immune and 
inflammatory gene responses in lambs of this study nebulized with RSV compared to those lambs 
inoculated with A2 by fiberoptic bronchoscope or intratracheally, maybe due to the slight difference in 
distribution of virus deposition that occurs with nebulization. 
Viral load as assessed by RT-qPCR has shown to peak at day 6 in our previous studies in lambs (22).  
By RT-qPCR there was no detectable RSV mRNA in control lambs while all infected lambs had 
detectable levels of RSV mRNA.  The day 6 p.i. termination point was selected because it provides 
time to collect additional clinical data and also time for development of peak gross and histologic 
lesions as well as increased levels of viral mRNA.  Tachypnea, wheeze, and increased expiratory effort 
were detected in lambs at day 6 p.i.  Unlike A2, the kinetics of M37 replication in lambs has not been 
fully elucidated, and earlier time points may be better for M37 virus isolation as shown in studies in 
mouse and cotton rat models where RSV replication often peaks at day 3 and 4 post inoculation (37). 
Overall, in this study there was a more dispersed pattern of lesions as compared to previous studies 
with intrabronchial inoculations with a fiberoptic bronchoscope or intratracheal inoculation (21, 22).  
Studies to compare virulence of M37 to A2 with different inoculation methods such as fiberoptic 
bronchoscope, intratracheal, and aerosol inoculation regimens may show subtle influences on viral 
replication and thereby may identify differences in disease severity caused by the two strains. 
The gross and histologic lesions had a slightly different character than previously observed with RSV 
in lambs and more lung lobes (especially the caudal lobes) had viral antigen compared to lambs 
infected by fiberoptic bronchoscope or intratracheally, although clinical and viral mRNA levels 
correlated with lesion severity.  The length of nebulization time may also affect viral deposition and 
lesion development.  In this study, lambs were nebulized for a longer time period (15 minutes) than 
used previously in our laboratory (10 minutes).  This type of inoculation may lead to a deeper 
deposition of the virus, causing the slightly more alveolar than bronchiolar lesions as well as a more 
histologically diffuse pattern of interstitial pneumonia.  Bronchiolitis with syncytia typical of RSV was 
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present, although the associated consolidation and inflammation observed in previous studies was 
more spread out from the bronchiole and had fewer neutrophils within lumina.  Grossly, the 
distribution of lesions was similar to previous nebulization experiments, but the color had a more 
grayish cast than the deep red lesions seen before, and these changes in color may be due to viral 
damage occurring at the alveolar level as opposed to viral infection predominantly centered on 
bronchioles.  However, the immunohistochemistry results verify antigen present in bronchiolar 
epithelium similar to that seen in this series of M37 studies.  
Route of inoculation (nebulized, intranasal, intratracheal, intrabronchial), viral dose and dilution, as 
well as lamb factors such as vendor source, colostrum deprivation, preterm birth, or age at inoculation 
can all be adjusted with the goal of creating low cost, manageable, reproducible models of moderate 
and severe RSV disease.  In this study we have shown that A2 and M37 will replicate and cause 
disease in perinatal lambs.  Additionally, route of inoculation may affect the pathology of RSV in 
neonatal lambs. 
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Figure 1. Clinical respiratory rate of lambs infected with 
  
M37-infected lambs had significantly higher
way ANOVA, p < 0.05. 
 
 
Figure 2. Representative gross lesions and gross lesion scoring in M37 and A2
lambs 
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 Figure 2, cont. 
 
Lungs of control lambs lack gross lesions.  Similar 
grossly in both the A2 and M37
involvement: 0% = 0, 1-9% = 1, 10
Tukey’s, P < 0.05. 
 
 
Figure 3.  Representative histologic lesions and scoring of lambs infected with hRSV
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 Figure 3, cont. 
Control lamb with normal alveoli and bronchioles.  A2 and M37
neutrophils, macrophages, and fewer lymphocytes a
infiltrates also are present within 
percent parenchymal consolidation where 0 = 0%, 1 = 1
of the infected groups had a higher histologic score than control lambs, by one
by Tukey’s method, p < 0.05. 
 
 
 
 
Figure 4. Immunohistochemical staining and scoring of immunoreactivity of RSV
infected lambs 
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Figure 4, cont. 
Control lamb lung lacked immunoreactivity for RSV.  A2 and M37
primarily within epithelial cells.  The number of positive fields/lamb was significantly different 
between all groups by ANOVA followed by Tukey’s method, with A2
staining.  Average slide score did 
number of positive fields.  Slides were scored on the following scale, based on number of 
immunoreactive cells/20X field: 0 = 0, 1
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Figure 5.  RT-qPCR results for RSV and innate immune targets 
 
Groups infected with RSV had detectable RSV mRNA levels, versus no RSV mRNA in control lambs.  
A2-infected lambs had significantly higher RSV levels than control lambs, although one lamb had no 
detectable viral mRNA. 
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CHAPTER 5: GENERAL CONCLUSIONS 
 
In an effort to further develop the lamb model of neonatal respiratory syncytial virus (RSV), this series 
of studies characterized the effects of a human strain of respiratory syncytial virus (hRSV) in the 
perinatal lamb: 
1. Memphis 37 (M37) strain hRSV caused moderate disease in perinatal lambs as measured by 
clinical disease (expiratory effort or tachypnea), post-mortem gross lesions, and histologic 
lesions with abundant RSV-antigen staining as well as significant viral mRNA levels. 
2. Nebulized Memphis 37 hRSV caused similar disease in lambs to hRSV strain A2. 
3. Memphis 37 hRSV grown in HEp-2 cells induced increased expiratory effort and greater 
lesion scores (gross and histologically) as well as increased antigen immunoreactivity as 
compared to Vero-grown M37. 
4. Nebulization and intranasal inoculation are reproducible methods of inoculation that caused a 
unique distribution pattern of lesions when compared to each other or fiberoptic intrabronchial 
inoculation. 
Memphis 37 Respiratory Syncytial Virus Causes Disease in Perinatal Lambs 
The central hypothesis revolved around M37 as a novel strain to use in RSV disease-modeling in 
perinatal lambs.  We have shown that M37 does cause disease, equal to or greater than previous 
studies in lambs.  Memphis 37 caused clinical alterations in respiration, as evidenced by wheeze, 
expiratory effort, and/or tachypnea.  Additionally, it caused gross and histologic lesions consistent 
with those seen in human disease as well as in previous work with RSV in lambs (1-3).  Further work 
is required to elucidate the altered gene expression of cytokines, chemokines, and immune proteins by 
M37, but there are trends in increased MIP1a, MCP1a, and IL-8 at day 6 p.i. 
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Strain Differences in Disease 
There are two major strains of RSV, A and B, and there are a number of genetic and antigenic 
differences between and within strains, which may account for some differences in disease (4-7).  
While some studies implicate RSV-A strain as more virulent than RSV-B (8), other studies could find 
no difference between the strains (9).  In mice, different substrains (A2 and Long strain) of RSV-A 
elicited unique cytokine profiles (10).  In vitro studies comparing A2 to clinical isolates also identified 
differences in viral growth, cytopathology and cytokine responses (11).  These findings may indicate 
the role that the virus strain serves in pathology.  When comparing two RSV-A strains, M37 and A2, 
M37 can cause clinical alterations in respiration not observed in previous A2 studies in lambs (2).  
However, in direct comparison of nebulized M37 and A2 strains, disease parameters are not 
significantly different except viral mRNA levels in A2 lambs are higher at day 6 p.i. 
Memphis 37 Grown in HEp-2 cells Causes More Severe Disease Than Vero-
grown M37 
Identification of a truncated G protein when M37 was propagated in Vero cells showed decreased 
infectivity and virulence in vitro (12).  In our studies, Vero-grown M37 caused minimal disease when 
inoculated intranasally and was not found after 3 or 6 days p.i. when nebulized.  In contrast to this, 
HEp-2 grown M37 virus caused robust disease with clinical respiratory symptoms of increased 
expiratory effort and gross lesions affecting a significantly greater portion of the lung than 
intranasally-inoculated Vero-grown M37.  
The G protein, while not essential for infectivity, is an attachment protein that triggers the fusion 
protein to bind to the host cell (a required step for RSV infection) (13, 14).  Virus lacking G 
glycoprotein is attenuated in vitro (12, 13), and now we have shown that Vero-grown RSV is also 
attenuated in vivo as compared to HEp-2 grown cells.  Interestingly, Vero-grown M37 can elicit mild 
upper respiratory symptoms in a percentage of adult subjects when inoculated intranasally (15).   
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Method of Inoculation Affects Lesion and Viral Antigen Distribution in the Lung 
While these studies had striking clinical and post-mortem findings, statistically significant changes in 
mRNA levels of cytokines and innate immunomodulatory proteins were generally lacking.  In most of 
the studies, there was a range of disease as noted by viral mRNA levels, altered respiration, and lesion 
scores.  While no animal was lacking viral mRNA at p.i. day 6, the variance in response increased the 
standard deviation, masking the true population characteristics.  Some trends that emerged were 
similar to differences previously observed in our laboratory as well as in epidemiologic studies in 
humans.  Notably, increases in MCP-1α and MIP-1α were observed at day 6 p.i, and IL-8 was 
observed in infected lambs but not in control lambs.  Similar increases were seen previously at day 6 
p.i. in lambs infected with A2 by bronchoscopically-guided inoculation (16).  
Future Directions 
Memphis 37 strain can be used to cause RSV disease in perinatal lambs.  Previously, bRSV has been 
shown to cause enhanced disease in preterm lambs; Memphis 37 has the potential for similar effects, 
and this may lead to the development of a severe disease model in lambs.  The use of human strains of 
RSV in lambs has some drawbacks as it does not appear to occur spontaneously in the natural setting; 
however, there are advantages to utilizing human strains in lambs for assessing antiviral compounds 
developed for human strains of RSV. 
Differences were observed in disease distribution and severity according to inoculation method.  
Exploring the parameters of intranasal and nebulized inoculation would help to create a very consistent 
and robust model.  For example, preliminary studies in vitro have shown low levels of RSV loss when 
nebulized.  Knowing the difference between strains or over the course of nebulization would help to 
refine this method of delivery.  In a non-human primate model of RSV using intranasal inoculation, 
the subjects were held supine for an extended period after viral inoculation (17); we tried both a head-
neutral position (M37 pilot studies) and a supine position (Vero vs. HEp-2 study) but did not compare 
them side by side and did not explore different amounts of time held in each position.  Previously our 
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lab has used either intratracheal inoculation (18) or intrabronchial inoculation via bronchoscopic 
guidance (2, 19).  Possibly a combination of methods, as has been used in bRSV studies in cattle (20) 
could yield a more consistent pattern of RSV infection. 
One of the few drawbacks of the lamb model of RSV is the lack of reagents and commercially-
available assays as compared to rodents.  While we have the capability to assess a number of targets of 
interest at the mRNA level, this does not necessarily reflect the level of active protein.  Assays such as 
Western blot or ELISA could and will be developed for the proteins of interest.  These could be useful 
in looking at protein levels of lung or lymph node homogenates, in bronchoalveolar lavage fluid 
(BALF), or even possibly in blood.  Additional laboratory tests could include reviewing the ratios of 
cytokines in previous as well as future studies.  In human epidemiology, ratios such as IL-8 to 
RANTES have shown statistical significance when absolute values of either factor alone have not (21). 
The overarching goal is to create a repeatable, useful model of moderate and/or severe disease to use in 
elucidating factors of disease severity and to test novel therapeutics.  A better understanding of how 
delivery methods affect the virus will be important in making future decisions in model development.  
Memphis 37 will cause disease in perinatal lambs and shows promise for use in a model of severe 
RSV disease. 
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